var title_f2_58_2976="Time to oxygen desaturation";
var content_f2_58_2976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F56716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F56716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Time to oxygen desaturation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 393px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Preoxygenation prolongs the period between paralysis with succinlycholine and oxygen desaturation in all patients, but to varying degrees depending on patient attributes. This diagram shows the time to desaturation for several different clinical conditions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Benumof JL, Dagg R, Benumof R. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology 1997; 87:979. Copyright &copy; 1997 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2976=[""].join("\n");
var outline_f2_58_2976=null;
var title_f2_58_2977="Anthrax vaccine adsorbed: Patient drug information";
var content_f2_58_2977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Anthrax vaccine adsorbed: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=see_link\">",
"     see \"Anthrax vaccine adsorbed: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BioThrax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10028765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_anthrax.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11083 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2977=[""].join("\n");
var outline_f2_58_2977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135675\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028765\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/58/18342?source=related_link\">",
"      Anthrax vaccine adsorbed: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_58_2978="Mediastinal lymphoma x ray";
var content_f2_58_2978=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal lymphoma chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PA (upper panel) and lateral (lower panel) radiographs of a patient with a large right-sided mediastinal mass (arrows). The biopsy was consistent with diffuse large B-cell non-Hodgkin's lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2978=[""].join("\n");
var outline_f2_58_2978=null;
var title_f2_58_2979="Temporary abdominal closure";
var content_f2_58_2979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70808&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Temporary abdominal closure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Temporary closure of the abdomen involves (A) covering the bowel with a fenestrated drape, (B) laying drains laterally and covering the bowel with a sterile towel, and (C) covering the wound with a sterile occlusive dressing with the drains exiting the drape superiorly (as shown) or inferiorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2979=[""].join("\n");
var outline_f2_58_2979=null;
var title_f2_58_2980="Microcystic type3 CPAM";
var content_f2_58_2980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Microcystic Type III CPAM at 24 weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial (A) and coronal (B) ultrasounds demonstrate a solid appearing echogenic mass in the left lower lobe causing mild displacement of the heart to the right. Oblique (C) T2w MRI images confirm the finding of a high signal mass in the left lower lobe. No arterial feeder and no hydrops were seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2980=[""].join("\n");
var outline_f2_58_2980=null;
var title_f2_58_2981="Temazepam: Patient drug information";
var content_f2_58_2981=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Temazepam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=see_link\">",
"     see \"Temazepam: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Restoril&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Temazepam&reg;;",
"     </li>",
"     <li>",
"      CO Temazepam;",
"     </li>",
"     <li>",
"      Dom-Temazepam;",
"     </li>",
"     <li>",
"      Gen-Temazepam;",
"     </li>",
"     <li>",
"      Novo-Temazepam;",
"     </li>",
"     <li>",
"      Nu-Temazepam;",
"     </li>",
"     <li>",
"      PHL-Temazepam;",
"     </li>",
"     <li>",
"      PMS-Temazepam;",
"     </li>",
"     <li>",
"      ratio-Temazepam;",
"     </li>",
"     <li>",
"      Restoril&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat panic attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to temazepam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for more than 10 days, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 to 60 minutes before bedtime if using for sleep. Do not take for more than 2 weeks in a row.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis. Do not take more often than every 24 hours unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11073 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2981=[""].join("\n");
var outline_f2_58_2981=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225182\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225183\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019545\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019547\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019546\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019551\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019552\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019554\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019549\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019550\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019555\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019556\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/44/27334?source=related_link\">",
"      Temazepam: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_58_2982="Pseudofolliculitis barbae - close view";
var content_f2_58_2982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudofolliculitis barbae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous erythematous and hyperpigmented papules are present on the beard area in this patient with pseudofolliculitis barbae.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2982=[""].join("\n");
var outline_f2_58_2982=null;
var title_f2_58_2983="Sitagliptin and metformin: Drug information";
var content_f2_58_2983=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sitagliptin and metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/2/9254?source=see_link\">",
"    see \"Sitagliptin and metformin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16339641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Investigating Unpublished Reports of Pancreatic Toxicity With Incretin Mimetic Drugs",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) is evaluating unpublished new findings that suggest an increased risk of pancreatitis and pancreatic duct metaplasia in patients with type 2 diabetes treated with incretin mimetics. These findings are based on pancreatic tissue samples taken from patients who died from unspecified causes. The FDA has requested these samples, as well as information on the methodology used to collect them, and will communicate its final conclusions and recommendations. Healthcare providers should continue to prescribe incretin mimetics according to the drug label recommendations and patients receiving incretin mimetics are advised to continue therapy as directed and to discuss any concerns with their healthcare provider.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following website:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm343187.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4476968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Janumet&reg;;",
"     </li>",
"     <li>",
"      Janumet&reg; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10107838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Janumet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4476972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Dipeptidyl Peptidase IV (DPP-IV) Inhibitor;",
"     </li>",
"     <li>",
"      Hypoglycemic Agent, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4476997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients receiving concomitant insulin and/or insulin secretagogues (eg, sulfonylureas) may require dosage adjustments of these agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Oral: Initial doses should be based on current dose of sitagliptin and metformin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Patients inadequately controlled on metformin alone:",
"     </i>",
"     Initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release: Sitagliptin 100 mg/day plus current daily dose of metformin given in 2 equally divided doses; maximum: sitagliptin 100 mg/metformin 2000 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     The U.S. labeling recommends patients currently receiving metformin 850 mg twice daily receive an initial dose of sitagliptin 50 mg and metformin 1000 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release: Sitagliptin 100 mg/day plus current daily dose of metformin given once daily; maximum: sitagliptin 100 mg/metformin 2000 mg daily.",
"     <b>",
"      Note:",
"     </b>",
"     The U.S. labeling recommends patients currently receiving immediate release metformin 850-1000 mg twice daily receive an initial dose of sitagliptin 100 mg and metformin 2000 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Patients inadequately controlled on sitagliptin alone:",
"     </i>",
"     Initial dose:",
"     <b>",
"      Note:",
"     </b>",
"     Patients currently receiving a renally-adjusted dose of sitagliptin should not be switched to a combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release: Metformin 1000 mg/day plus sitagliptin 100  mg/day given in 2 equally divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release: Metformin 1000 mg and sitagliptin 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Conversion from immediate release to extended release:",
"     </i>",
"     Convert using same total daily dose (up to the maximum recommended dose), but adjust frequency as indicated for immediate (twice daily) or extended (once daily) release products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosing adjustment:",
"     </b>",
"     Metformin component may be gradually increased up to the maximum dose. Maximum dose: Sitagliptin 100 mg/metformin 2000 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4476998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor). Do not use in patients &ge;80 years of age unless normal renal function has been established.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4476999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use with renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL [&ge;136 micromole/L] in males or &ge;1.4 mg/dL [&ge;124 micromole/L] in females or abnormal clearance).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4477000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid metformin; liver disease is a risk factor for the development of lactic acidosis during metformin therapy.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4477006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Janumet&reg; 50/500: Sitagliptin 50 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Janumet&reg; 50/1000: Sitagliptin 50 mg and metformin hydrochloride 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Janumet&reg; XR: 50/500: Sitagliptin 50 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Janumet&reg; XR: 50/1000: Sitagliptin 50 mg and metformin hydrochloride 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Janumet&reg; XR: 100/1000: Sitagliptin 100 mg and metformin hydrochloride 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10824144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Janumet&reg; 50/850: Sitagliptin 50 mg and metformin hydrochloride 850 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4476970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10107837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Janumet&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM204268.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM204268.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Janumet&reg; XR:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM291878.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM291878.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4477002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals, at the same time each day (evening meal preferable for extended release tablets). Swallow extended release tablets whole; do not split, crush, or chew; do not split or divide regular release tablets.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4476973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise in patients not adequately controlled on metformin or sitagliptin monotherapy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6266685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Janumet&reg; may be confused with Jantoven&reg;, Januvia&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sitagliptin and Metformin  may be confused with Linagliptin and Metformin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sitagliptin and Metformin  may be confused with Saxagliptin and Metformin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4476984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4476979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sitagliptin, metformin, or any component of the formulation; renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL [&ge;136 &mu;mol/L] in males or &ge;1.4 mg/dL [&ge;124 &mu;mol/L] in females), or abnormal creatinine clearance which may also result from conditions such as cardiovascular collapse, acute myocardial infarction, and septicemia); acute or chronic metabolic acidosis including diabetic ketoacidosis (with or without coma).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Unstable and/or insulin-dependent (type 1) diabetes mellitus (IDDM); history of lactic acidosis, regardless of precipitating factors; acute or chronic excessive alcohol intake; severe hepatic disease; cardiovascular collapse and disease states associated with hypoxemia (eg, cardiorespiratory insufficiency) which are often associated with hyperlactacidemia; use during stress conditions (eg, severe infection, trauma, surgery) and the recovery phase thereafter; severe dehydration; breast-feeding; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4476980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Rare hypersensitivity reactions (including anaphylaxis, angioedema and/or severe dermatologic reactions, such as Stevens-Johnson syndrome) have been reported in postmarketing surveillance; discontinue if signs/symptoms of hypersensitivity reactions occur. Events have generally been noted within the first 3 months of therapy, and may occur with the initial dose. Use with caution if patient has experienced angioedema with other DPP-IV inhibitor use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis:",
"     <b>",
"      [U.S. Boxed Warning]: Lactic acidosis is a rare, but potentially severe consequence of therapy with metformin.",
"     </b>",
"     Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue metformin in clinical situations predisposing to hypoxemia, including conditions such as cardiovascular collapse, respiratory failure, acute myocardial infarction, acute congestive heart failure, and septicemia. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Diabetes mellitus (type 1): Not indicated for use in patients with insulin-dependent diabetes mellitus (IDDM) (type 1) due to lack of efficacy in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heart failure: Use with caution in patients with congestive heart failure requiring pharmacologic management, particularly in patients with unstable acute heart failure; risk of lactic acidosis may be increased secondary to hypoperfusion. The Canadian labeling recommends avoiding use in patients with heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Avoid metformin use in patients with impaired liver function due to potential for lactic acidosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pancreatitis: Cases of acute pancreatitis (including hemorrhagic and necrotizing with some fatalities) have been reported with use. Monitor for signs/symptoms of pancreatitis; discontinue use immediately if pancreatitis is suspected and initiate appropriate management. Use with caution in patients with a history of pancreatitis as it is not known if this population is at greater risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin: Use caution when used in conjunction with insulin; risk of hypoglycemia is increased. Monitor blood glucose closely; insulin dosage adjustments may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Insulin secretagogues: Concomitant use of an insulin secretagogue (eg, sulfonylurea) may increase the risk of hypoglycemia. Monitor blood glucose closely; dosage reduction of secretagogues may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Metformin should not be initiated in patients &ge;80 years of age unless normal renal function is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodinated contrast: Metformin therapy should  be temporarily discontinued prior to or at the time of  intravascular administration of iodinated contrast media (potential for acute alteration in renal function). Metformin should be withheld for 48 hours after the radiologic study and restarted only after renal function has been confirmed as normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Surgical procedures: Therapy should be suspended for any surgical procedures (resume only after normal intake resumed and normal renal function is verified).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     concentrations: May impair vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     absorption, particularly in those with inadequate vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     or calcium intake/absorption; very rarely associated with anemia. Rapid reversal of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency may be observed with discontinuation of therapy or supplementation. Monitor vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     serum concentrations periodically with long-term therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4476987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: DPP-IV Inhibitors may enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: SitaGLIPtin may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4476988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive ethanol intake (acute or chronic) should be avoided due to increased risks for metformin accumulation and lactic acidosis.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4476974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4476975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Reproduction studies have not been conducted with this combination. Adverse events were not observed in animal studies of the individual agents; therefore, sitagliptin/metformin is classified as pregnancy category B. See individual agents. Health professionals are encouraged to report any prenatal exposure to Janumet&reg; by contacting Merck&rsquo;s pregnancy registry (1-800-986-8999).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4476977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sitagliptin: Excretion in breast milk unknown/use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metformin: Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4476978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4477001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with meals (to decrease GI upset). Take at the same time each day. Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy. Monitor for signs and symptoms of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and/or folic acid deficiency; supplementation may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4735728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Janumet XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-500 mg (180): $885.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-1000 mg (180): $885.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-1000 mg (90): $885.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Janumet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-500 mg (180): $885.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-1000 mg (180): $885.42",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4477004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     and serum glucose, hematologic parameters (eg, hemoglobin/hematocrit, red blood cell indices); hepatic function, renal function (prior to initiation of therapy then annually or more frequent if necessary); vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     (periodically with long-term treatment) and folate (if megaloblastic anemia is suspected)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4476992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Efficib (EE);",
"     </li>",
"     <li>",
"      Januet (IL);",
"     </li>",
"     <li>",
"      Janumet (AR, AT, AU, BE, BR, CH, CN, CO, CR, CZ, DE, DK, EE, FR, GB, GR, GT, HK, HN, ID, IE, IN, IT, KP, MY, NI, NL, NO, NZ, PE, PH, PL, PT, SE, SG, SV, TH, TW);",
"     </li>",
"     <li>",
"      Velmetia (AT, CH, CZ, DE, EE, FR, IT, NL, PL, PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4476991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sitagliptin inhibits dipeptidyl peptidase IV (DPP-IV) enzymes resulting in prolonged active incretin levels. Incretin hormones [eg, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)] regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from pancreatic alpha cells. Decreased glucagon secretion results in decreased hepatic glucose production. Under normal physiologic circumstances, incretin hormones are released by the intestine throughout the day and levels are increased in response to a meal; incretin hormones are rapidly inactivated by DPP-IV enzymes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Metformin decreases hepatic glucose production, decreasing intestinal absorption of glucose, and improves insulin sensitivity (increases peripheral glucose uptake and utilization).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4476993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/58/2983/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/58/2983/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/58/2983/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10245 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2983=[""].join("\n");
var outline_f2_58_2983=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16339641\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709412\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476968\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10107838\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476972\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476997\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476998\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476999\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4477000\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4477006\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824144\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476970\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10107837\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4477002\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476973\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6266685\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476984\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476979\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476980\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838537\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476987\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476988\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476974\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476975\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476977\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476978\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4477001\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4735728\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4477004\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476992\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961930\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476991\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476993\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10245\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10245|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/2/9254?source=related_link\">",
"      Sitagliptin and metformin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_58_2984="Large gastric folds: Hyperplastic and nonhyperplastic gastropathies";
var content_f2_58_2984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Large gastric folds: Hyperplastic and nonhyperplastic gastropathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/58/2984/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2984/contributors\">",
"     Beverly A Dickson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2984/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/58/2984/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2984/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/58/2984/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2984/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/58/2984/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of proliferative, inflammatory, and infiltrative conditions are associated with enlarged or giant mucosal folds in the stomach (diffuse mucosal hypertrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/1\">",
"     1",
"    </a>",
"    ]. These conditions have a similar appearance despite primary involvement of the mucosa, submucosa, or both in specific conditions. Thus, the underlying cause of the large mucosal folds cannot be determined from gross observation alone.",
"   </p>",
"   <p>",
"    In one series, endoscopic snare biopsy was performed in 52 patients with large gastric folds (greater than 1.0 cm in width and persisting after air insufflation) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/2\">",
"     2",
"    </a>",
"    ]. The diagnoses included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic",
"      <span class=\"nowrap\">",
"       gastritis/lymphoid",
"      </span>",
"      hyperplasia &ndash; 40 percent",
"     </li>",
"     <li>",
"      Benign tumors &ndash; 16 percent",
"     </li>",
"     <li>",
"      Gastric malignancy &ndash; 12 percent",
"     </li>",
"     <li>",
"      Zollinger-Ellison syndrome &ndash; 10 percent",
"     </li>",
"     <li>",
"      M&eacute;n&eacute;trier's disease &ndash; 8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic reviews the major disorders considered in the differential diagnosis of large gastric folds. Some of these disorders are discussed in detail individually. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link\">",
"     \"Metaplastic (chronic) atrophic gastritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperplasia &ndash; an increase in intrinsic organ cell number.",
"     </li>",
"     <li>",
"      Hypertrophy &ndash; an increase in the volume of an organ. Hypertrophy may be hyperplastic or nonhyperplastic.",
"     </li>",
"     <li>",
"      Diffuse mucosal hypertrophy &ndash; Diffuse mucosal hypertrophy refers to a phenomenon of enlarged or giant gastric folds. Diffuse mucosal hypertrophy may be hyperplastic or nonhyperplastic:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hyperplastic gastropathy &ndash; The gastric epithelial cells which compose the oxyntic glands may become hyperplastic and give rise to giant mucosal folds. Hyperplastic gastropathies include: M&eacute;n&eacute;trier's disease, hyperplastic hypersecretory gastropathy, and Zollinger-Ellison syndrome.",
"     </li>",
"     <li>",
"      Nonhyperplastic gastropathy &ndash; The gastric mucosa may contain other cell types which result in enlargement of the gastric folds. Large gastric folds associated with other conditions include: various gastridities, infiltrative diseases, infections, and malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gastric mucosa is composed of two compartments, the superficial mucosa, which includes the surface mucous cells and foveolar cells and the deep compartment which is composed of the specialized epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/3\">",
"     3",
"    </a>",
"    ]. The surface and pit (foveolas) of the gastric gland are composed of surface cells and foveolar cells lining the superficial portions of the gastric pit. Slightly deeper in the gland is the isthmus (which is the location of the progenitor cells) and the mucous neck cells. The base of the gland contains the specialized epithelium which includes the enterochromaffin cell (serotonin), the enterochromaffin-like cell (histamine), the chief cell (pepsinogen), the D cell (somatostatin), and the parietal cell (acid and intrinsic factor).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HYPERPLASTIC GASTROPATHIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     M&eacute;n&eacute;trier's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;M&eacute;n&eacute;trier's disease (also called protein-losing hypertrophic gastropathy) is a rare acquired condition of the stomach which is most common in middle-aged males, but which occurs in both genders and in children as a special pediatric variant. The disease is usually progressive in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of M&eacute;n&eacute;trier's disease is not well understood. It is thought that it involves increased signaling of the epidermal growth factor receptor (EGFR) which results in proliferation of epithelial cells of the mucous cell compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The hyperplastic cell type in M&eacute;n&eacute;trier's is the mucous cell. The enhanced activity of EGFR in M&eacute;n&eacute;trier's is related to overproduction of transforming growth factor-alpha (TGF-alpha), a ligand that can bind and activate EGFR. TGF-alpha is produced by the oxyntic mucosa, predominantly by the parietal cells; however, the molecular defect that results in the localized upregulation of TGF-alpha is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. TGF-alpha is known to stimulate growth of epithelial cells and inhibit gastric acid secretion. The decreased acid production is due to both direct effects on the parietal cells and indirectly via stimulation of somatostatin release.",
"   </p>",
"   <p>",
"    An alternative hypothesis for the pathogenesis of M&eacute;n&eacute;trier's disease suggests that malfunction of the histamine H2-receptors may result in oxyntic hyperplasia and hypoalbuminemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. M&eacute;n&eacute;trier's has occurred after prolonged treatment with H2-receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytomegalovirus (CMV) is postulated to be an important cause of pediatric M&eacute;n&eacute;trier's disease. One-third of the children with M&eacute;n&eacute;trier's reportedly have CMV-associated M&eacute;n&eacute;trier's disease, which usually spontaneously resolves in two to four weeks. It has been difficult to prove that an actual infection with CMV is present in these pediatric cases, due to the high prevalence of CMV in children. It is interesting, however, that one study suggested that CMV infects cells by interacting with EGFR thereby activating tyrosine kinase, a requirement for viral particle entry [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. TGF-alpha was found to be increased by immunohistochemistry in one childhood and one adult case of CMV-associated M&eacute;n&eacute;trier's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. As the CMV virus is cleared from the system, the stimulus to the EGFR is decreased, thus resulting in less TGF-alpha production, lessened cell proliferation, and a return to normal anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with M&eacute;n&eacute;trier's disease can present with a variety of clinical features including epigastric pain, substantial weight loss, nausea, vomiting, gastrointestinal bleeding, diarrhea, and protein-losing gastroenteropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .) In one series of 40 patients without satisfactory biopsy confirmation of M&eacute;n&eacute;trier's disease, the main complaints were [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Epigastric pain &ndash; 65 percent",
"     </li>",
"     <li>",
"      Asthenia &ndash; 60 percent",
"     </li>",
"     <li>",
"      Anorexia &ndash; 45 percent",
"     </li>",
"     <li>",
"      Weight loss &ndash; 45 percent",
"     </li>",
"     <li>",
"      Edema &ndash; 38 percent",
"     </li>",
"     <li>",
"      Vomiting &ndash; 38 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, approximately 80 percent of patients had hypoalbuminemia and increased enteric protein loss. In other series, hypoalbuminemia was present in 20 to 100 percent of patients, but its presence did not distinguish M&eacute;n&eacute;trier's disease from other causes of giant gastric folds, with the exception of the Zollinger-Ellison syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/12-14,16,17\">",
"     12-14,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Basal and stimulated gastric acid secretion is usually low or normal in M&eacute;n&eacute;trier's disease, but varies depending upon the point in the disease course when determinations are made [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/12,14,17,18\">",
"     12,14,17,18",
"    </a>",
"    ]. Small to moderate elevation of serum gastrin may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional clinical features such as edema, ascites, pleural and pericardial effusions, as well as laboratory abnormalities such as hypoalbuminemia without proteinuria, lymphopenia, malabsorption of fat and fat-soluble vitamins, and reduced plasma concentrations of gamma globulins, cholesterol, alpha-1 antitrypsin, fibrinogen and ceruloplasmin are similar to those in other forms of protein-losing gastroenteropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of M&eacute;n&eacute;trier's disease is established on biopsy by the demonstration of extreme foveolar hyperplasia with glandular atrophy in a patient with striking enlargement of gastric folds or rugae seen on endoscopy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    radiography. A full-thickness biopsy (or endoscopic snare or suction biopsy) is usually required [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/17,20\">",
"     17,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The enlarged folds are confined to the body and fundus (",
"    <a class=\"graphic graphic_picture graphicRef63252 \" href=\"UTD.htm?39/37/40533\">",
"     picture 1",
"    </a>",
"    ). The folds are usually enlarged symmetrically, although asymmetric enlargement with a polypoid appearance may be encountered rarely.",
"   </p>",
"   <p>",
"    Tests for CMV and Helicobacter pylori should be performed since these infectious agents should be treated if found. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Helicobacter pylori gastritis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Distinguishing M&eacute;n&eacute;trier's disease from disorders that mimic it may be difficult. Polyposis syndromes are the most common mimics of M&eacute;n&eacute;trier's disease and are distinguished by genetic testing,&nbsp;history of familial polyposis, and extra-gastric&nbsp;symptomatology. In a study of patients being referred for treatment of M&eacute;n&eacute;trier's disease, the diagnosis was confirmed in 25 of 48 patients (52 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/21\">",
"     21",
"    </a>",
"    ]. The most common diagnoses in the remainder were gastric polyps and polyposis syndromes (13 of 48 patients, 28 percent). Compared with patients with alternate diagnoses, patients with M&eacute;n&eacute;trier's disease were younger, more often male, more likely to complain of vomiting, and more likely to present with peripheral edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2361?source=see_link\">",
"     \"Gastric polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple medical treatments have been utilized in patients with M&eacute;n&eacute;trier's disease; however, controlled trials are lacking and most pharmacologic treatments do not seem to provide consistent benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       CMV/Helicobacter",
"      </span>",
"      treatment - Tests for CMV and Helicobacter pylori should be performed, as some cases of diffuse mucosal hypertrophy do resolve with treatment of these infectious agents if detected (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Helicobacter pylori gastritis'",
"      </a>",
"      below).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       Ganciclovir",
"      </a>",
"      may be of benefit in CMV associated M&eacute;n&eacute;trier's disease in children [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastric antisecretory agents - A trial of a proton pump inhibitor or histamine-2 receptor antagonist drug is frequently performed while monitoring of the patient for a reduction in symptoms and signs (eg, edema) and of serum protein levels.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       Octreotide",
"      </a>",
"      &ndash; The somatostatin analogue octreotide, 100 to 600 micrograms daily subcutaneously or intravenously in two to four divided doses, or octreotide LAR (depot formulation) 10 to 60 mg intramuscularly every four weeks has been used in case reports, although it is not FDA approved for treatment of M&eacute;n&eacute;trier's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Clinical improvement of symptoms was apparent in several days. Molecular evidence suggests that octreotide may regulate EGFR signaling downstream [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Monoclonal antibodies &ndash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/58/10151?source=see_link\">",
"       Cetuximab",
"      </a>",
"      , a monoclonal antibody to epidermal growth factor receptor (EGFR) has been used to treat M&eacute;n&eacute;trier's disease. In small case series, cetuximab was found to be successful in treating patients with disease-related refractory symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/26\">",
"       26",
"      </a>",
"      ]. In another uncontrolled study, cetuximab was used to treat nine patients with M&eacute;n&eacute;trier's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/27\">",
"       27",
"      </a>",
"      ]. Of the seven patients who completed the one month course of treatment, four had almost complete reversal of the histologic features of M&eacute;n&eacute;trier's in the gastric mucosa. All seven patients demonstrated statistically significant improvement in quality-of-life indices as well as in biochemical measures (gastric acidity) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/27\">",
"       27",
"      </a>",
"      ]. The FDA has allowed cetuximab to be used on a compassionate need basis in some patients with M&eacute;n&eacute;trier's disease.",
"     </li>",
"     <li>",
"      Gastrectomy &ndash; Gastrectomy is reserved for those patients with intractable symptoms and signs refractory to medical therapy. Even though M&eacute;n&eacute;trier's disease is primarily a disease of the gastric fundus and body, a total gastrectomy is the surgery of choice due to the reduced surgical complications and improved quality of life versus a proximal gastrectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of M&eacute;n&eacute;trier's disease is not well understood. In adults the disease is usually progressive, although there are a few reported cases of resolution in adults after treatment of Helicobacter pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. In children, the disease may resolve spontaneously or after treatment of CMV infection with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association of M&eacute;n&eacute;trier's disease with ulcerative colitis has been reported, though the prevalence of the association is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether there is an increased risk of gastric adenocarcinoma in patients with M&eacute;n&eacute;trier's disease is uncertain, with risk estimates varying from 2 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/12,14,17,32,33\">",
"     12,14,17,32,33",
"    </a>",
"    ]. In many studies that relate M&eacute;n&eacute;trier's disease to cancer, adequate histologic confirmation of the two conditions is lacking. In the past, the treatment of M&eacute;n&eacute;trier's disease was gastric resection, so cancer risk could not be accurately determined [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/34\">",
"     34",
"    </a>",
"    ]. The authors recommend endoscopic surveillance every one to two years for early detection of neoplasia or dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Zollinger-Ellison syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zollinger-Ellison syndrome (gastric acid hypersecretion due to a gastrinoma) is a hyperplastic gastropathy involving the body and fundus of the stomach. One hyperplastic cell type in Zollinger-Ellison syndrome is the parietal cell that results in the hypersecretion of gastric acid. There is also an increase in histamine-secreting enterochromaffin-like cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LARGE GASTRIC FOLDS ASSOCIATED WITH OTHER CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large gastric folds have also been described in a variety of other conditions including glandular hyperplasia (hypertrophic glandular gastritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/28\">",
"     28",
"    </a>",
"    ], gastric hypersecretion with or without hypoalbuminemia (hypertrophic hypersecretory gastropathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/14,35-38\">",
"     14,35-38",
"    </a>",
"    ], hyperplastic hypersecretory gastropathy (Schindler's disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/39\">",
"     39",
"    </a>",
"    ], Helicobacter pylori gastritis, and neoplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Helicobacter pylori gastritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute gastritis due to Helicobacter pylori (H. pylori) can be associated with striking acute inflammation and enlarged gastric folds giving the impression of a gastric malignancy. Chronic H. pylori gastritis may also be associated with enlarged gastric folds, mimicking the findings in M&eacute;n&eacute;trier's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In a report of 48 patients biopsied with isolated thickened gastric folds, chronic active gastritis was identified most frequently on biopsy (81 percent), with evidence of H. pylori in 92 percent of those biopsied [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=see_link\">",
"     \"Acute and chronic gastritis due to Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observations have suggested an association between gastritis due to H. pylori and enlarged gastric folds [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/28-30,37-39,43\">",
"     28-30,37-39,43",
"    </a>",
"    ]. In one series, 18 of 32 patients with thickened gastric folds were infected with H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/29\">",
"     29",
"    </a>",
"    ]. Anti-H. pylori therapy led to normalization of gastric fold size. Similar findings have been noted in other case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/30,43\">",
"     30,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of diffuse mucosal hypertrophy in H. pylori gastritis is uncertain. One case report suggested that production of an enteroendocrine mucosal growth factor, glucagon-like peptide (GLP-2), is upregulated in H. pylori infection. It is hypothesized that the increase in this trophic hormone may result in the formation of giant folds, which then recede along with the serum GLP-2 levels with resolution of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study demonstrated different levels of cytokine production associated with different strains of Helicobacter pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/45\">",
"     45",
"    </a>",
"    ]. They found that the H. pylori isolated from a patient with M&eacute;n&eacute;trier's disease induced the production of high levels of hepatocyte growth factor (HGF) mRNA expression. HGF has been reported to alter the tight junctions of gastric epithelial cells, which would lead to protein loss. The increased HGF caused by certain strains of H. pylori may explain the pathogenesis of M&eacute;n&eacute;trier's disease in some patients who have M&eacute;n&eacute;trier's disease and H. pylori.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplasms, particularly lymphoma, adenocarcinoma, and carcinoid tumors, should be excluded in patients with enlarged gastric folds [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/2\">",
"     2",
"    </a>",
"    ]. Endoscopic ultrasound may be helpful in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/46\">",
"     46",
"    </a>",
"    ]; however, biopsy is needed to make the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"     \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Miscellaneous causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other diseases may be associated with large gastric folds including lymphocytic gastritis (",
"    <a class=\"graphic graphic_picture graphicRef66689 \" href=\"UTD.htm?13/57/14231\">",
"     picture 2",
"    </a>",
"    ) (which may be related in some cases to H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]), sarcoidosis, eosinophilic gastroenteritis, and Cronkhite-Canada syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=see_link\">",
"     \"Gastrointestinal sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes are glandular hyperplasia (hypertrophic glandular gastritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/28\">",
"     28",
"    </a>",
"    ], gastric hypersecretion with or without hypoalbuminemia (hypertrophic hypersecretory gastropathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/14,35-38\">",
"     14,35-38",
"    </a>",
"    ], and hyperplastic hypersecretory gastropathy (Schindler's disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2984/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of proliferative, inflammatory, and infiltrative conditions are associated with enlarged or giant mucosal folds in the stomach (diffuse mucosal hypertrophy). Diffuse mucosal hypertrophy may be hyperplastic or nonhyperplastic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperplastic gastropathies include: M&eacute;n&eacute;trier's disease, hyperplastic hypersecretory gastropathy, and Zollinger-Ellison syndrome. Large gastric folds associated with other conditions include: various gastridities, infiltrative diseases, infections, and malignancy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hyperplastic gastropathies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Large gastric folds associated with other conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M&eacute;n&eacute;trier's disease is a rare acquired condition of the stomach. Patients with M&eacute;n&eacute;trier's disease can present with a variety of clinical features including epigastric pain, substantial weight loss, nausea, vomiting, gastrointestinal bleeding, diarrhea, and protein-losing gastroenteropathy with edema formation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'M&eacute;n&eacute;trier's disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polyposis syndromes (the most common mimics of M&eacute;n&eacute;trier's disease) are distinguished by genetic testing,&nbsp;history of familial polyposis, and extra-gastric&nbsp;symptomatology. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The diagnosis of M&eacute;n&eacute;trier's disease is established by a gastric biopsy showing extreme foveolar hyperplasia with glandular atrophy in a patient with striking enlargement of gastric folds or rugae seen on endoscopy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      radiography. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple medical treatments for M&eacute;n&eacute;trier's disease have been utilized (cytomegalovirus",
"      <span class=\"nowrap\">",
"       [CMV]/Helicobacter",
"      </span>",
"      treatment, gastric antisecretory agents, somatostatin analogues, monoclonal antibodies to the epidermal growth factor receptor [EGFR]), although more trials are needed. Our approach is to treat Helicobacter pylori or CMV infection, if present. If absent, we perform a one- to three-month trial of a proton pump inhibitor given twice daily. Should this trial fail, either a trial of a monoclonal antibody to epidermal growth factor receptor (EGFR) or total gastrectomy is warranted. In rare cases with massive or unrelenting bleeding that is uncontrollable endoscopically, gastrectomy will be required. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because M&eacute;n&eacute;trier's disease is associated with gastric cancer, we recommend endoscopic surveillance every one to two years. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zollinger-Ellison syndrome (hypersecretion of gastrin due to a gastrinoma) is a hyperplastic gastropathy involving the body and fundus of the stomach. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Large gastric folds have also been described in a variety of other conditions including glandular hyperplasia, gastric hypersecretion with or without hypoalbuminemia, Helicobacter pylori gastritis, and neoplasia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Helicobacter pylori gastritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Neoplasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Miscellaneous causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Yardley JH, Hendrix TR. Gastritis, duodenitis, and associated ulcerative lesions. In: Textbook of Gastroenterology, 3rd ed, Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE (Eds), Lippincott, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/2\">",
"      Komorowski RA, Caya JG, Geenen JE. The morphologic spectrum of large gastric folds: utility of the snare biopsy. Gastrointest Endosc 1986; 32:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/3\">",
"      Toubia N, Schubert ML. Menetrier's Disease. Curr Treat Options Gastroenterol 2008; 11:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/4\">",
"      Dempsey PJ, Goldenring JR, Soroka CJ, et al. Possible role of transforming growth factor alpha in the pathogenesis of M&eacute;n&eacute;trier's disease: supportive evidence form humans and transgenic mice. Gastroenterology 1992; 103:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/5\">",
"      Coffey RJ, Washington MK, Corless CL, Heinrich MC. M&eacute;n&eacute;trier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J Clin Invest 2007; 117:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/6\">",
"      Rothenberg M, Pai R, Stuart K. Successful use of octreotide to treat M&eacute;n&eacute;trier's disease: a rare cause of abdominal pain, weight loss, edema, and hypoalbuminemia. Dig Dis Sci 2009; 54:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/7\">",
"      Chen D, Aihara T, Zhao CM, et al. Differentiation of the gastric mucosa. I. Role of histamine in control of function and integrity of oxyntic mucosa: understanding gastric physiology through disruption of targeted genes. Am J Physiol Gastrointest Liver Physiol 2006; 291:G539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/8\">",
"      Geist M, Fich A, Mogle P. Menetrier's disease: evolution of disease under histamine-2 receptor antagonists. Am J Gastroenterol 1992; 87:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/9\">",
"      Nalle SC, Turner JR. Menetrier's disease therapy: rebooting mucosal signaling. Sci Transl Med 2009; 1:8ps10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/10\">",
"      Wang X, Huong SM, Chiu ML, et al. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 2003; 424:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/11\">",
"      Sferra TJ, Pawel BR, Qualman SJ, Li BU. M&eacute;n&eacute;trier disease of childhood: role of cytomegalovirus and transforming growth factor alpha. J Pediatr 1996; 128:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/12\">",
"      Scharschmidt BF. The natural history of hypertrophic gastrophy (Menetrier's disease). Report of a case with 16 year follow-up and review of 120 cases from the literature. Am J Med 1977; 63:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/13\">",
"      Searcy RM, Malagelada JR. M&eacute;n&eacute;tri&egrave;r's disease and idiopathic hypertrophic gastropathy. Ann Intern Med 1984; 100:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/14\">",
"      Fieber SS, Rickert RR. Hyperplastic Gastropathy. Analysis of 50 selected cases from 1955-1980. Am J Gastroenterol 1981; 76:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/15\">",
"      Meuwissen SG, Ridwan BU, Hasper HJ, Innemee G. Hypertrophic protein-losing gastropathy. A retrospective analysis of 40 cases in The Netherlands. The Dutch M&eacute;n&eacute;trier Study Group. Scand J Gastroenterol Suppl 1992; 194:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/16\">",
"      Kelly DG, Miller LJ, Malagelada JR, et al. Giant hypertrophic gastropathy (M&eacute;n&eacute;trier's disease): pharmacologic effects on protein leakage and mucosal ultrastructure. Gastroenterology 1982; 83:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/17\">",
"      Sundt TM 3rd, Compton CC, Malt RA. M&eacute;n&eacute;trier's disease. A trivalent gastropathy. Ann Surg 1988; 208:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/18\">",
"      Berry EM, Ben-Dov Y, Freund U. Spontaneous remission of protein-losing gastropathy associated with Menetrier's disease. A plea for conservative management. Arch Intern Med 1980; 140:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/19\">",
"      Komorowski RA, Caya JG. Hyperplastic gastropathy. Clinicopathologic correlation. Am J Surg Pathol 1991; 15:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/20\">",
"      Wolfsen HC, Carpenter HA, Talley NJ. Menetrier's disease: a form of hypertrophic gastropathy or gastritis? Gastroenterology 1993; 104:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/21\">",
"      Rich A, Toro TZ, Tanksley J, et al. Distinguishing M&eacute;n&eacute;trier's disease from its mimics. Gut 2010; 59:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/22\">",
"      Hoffer V, Finkelstein Y, Balter J, et al. Ganciclovir treatment in M&eacute;n&eacute;trier's disease. Acta Paediatr 2003; 92:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/23\">",
"      Wald A, Frenkel LM, Benjamin DL, Christie DL. Cytomegalovirus gastropathy in a child: resolution after ganciclovir therapy. Clin Infect Dis 1998; 26:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/24\">",
"      Yeaton P, Frierson HF Jr. Octreotide reduces enteral protein losses in M&eacute;n&eacute;trier's disease. Am J Gastroenterol 1993; 88:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/25\">",
"      Green BT, Branch MS. Menetrier's disease treated with octreotide long-acting release. Gastrointest Endosc 2004; 60:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/26\">",
"      Settle SH, Washington K, Lind C, et al. Chronic treatment of M&eacute;n&eacute;trier's disease with Erbitux: clinical efficacy and insight into pathophysiology. Clin Gastroenterol Hepatol 2005; 3:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/27\">",
"      Fiske WH, Tanksley J, Nam KT, et al. Efficacy of cetuximab in the treatment of Menetrier's disease. Sci Transl Med 2009; 1:8ra18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/28\">",
"      Groisman GM, George J, Berman D, Harpaz N. Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori. Am J Gastroenterol 1994; 89:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/29\">",
"      Kawasaki M, Hizawa K, Aoyagi K, et al. M&eacute;n&eacute;tri&egrave;r's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. Am J Gastroenterol 1997; 92:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/30\">",
"      Bayerd&ouml;rffer E, Ritter MM, Hatz R, et al. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori--is Helicobacter pylori a pathogenic factor in M&eacute;n&eacute;trier's disease? Gut 1994; 35:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/31\">",
"      Madisch A, Miehlke S, Neuber F, et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. Aliment Pharmacol Ther 2006; 23:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/32\">",
"      CHUSID EL, HIRSCH RL, COLCHER H. SPECTRUM OF HYPERTROPHIC GASTROPATHY; GIANT RUGAL FOLDS, POLYPOSIS, AND CARCINOMA OF THE STOMACH--CASE REPORT AND REVIEW OF THE LITERATURE. Arch Intern Med 1964; 114:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/33\">",
"      Wood MG, Bates C, Brown RC, Losowsky MS. Intramucosal carcinoma of the gastric antrum complicating Menetrier's disease. J Clin Pathol 1983; 36:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/34\">",
"      Spengel K, Olyaee M, Fan F. Pathologic quiz case: a 39-year-old woman with nausea, vomiting, diarrhea, and weight loss. M&eacute;n&eacute;trier disease. Arch Pathol Lab Med 2005; 129:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/35\">",
"      Overholt BF, Jeffries GH. Hypertrophic, hypersecretory protein-losing gastropathy. Gastroenterology 1970; 58:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/36\">",
"      Brooks AM, Isenberg J, Goldstein H. Giant thickening of the gastric mucosa with acid hypersecretion and protein-losing gastropathy. Gastroenterology 1970; 58:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/37\">",
"      STEMPIEN SJ, DAGRADI AE, REINGOLD IM, et al. HYPERTROPHIC HYPERSECRETORY GASTROPATHY. ANALYSIS OF 15 CASES AND A REVIEW OF THE PERTINENT LITERATURE. Am J Dig Dis 1964; 9:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/38\">",
"      Tan DT, Stempien SJ, Dagradi AE. The clinical spectrum of hypertrophic hypersecretory gastropathy. Report of 50 patients. Gastrointest Endosc 1971; 18:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/39\">",
"      Simson JN. Hyperplastic gastropathy. Br Med J (Clin Res Ed) 1985; 291:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/40\">",
"      Herz R, Lombardi E, Wipping F, Stolte M. [Helicobacter pylori-associated hypertrophic gastritis. Imitation of M&eacute;n&eacute;trier disease]. Fortschr Med 1992; 110:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/41\">",
"      Stolte M, B&auml;tz C, Eidt S. Giant fold gastritis--a special form of Helicobacter pylori associated gastritis. Z Gastroenterol 1993; 31:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/42\">",
"      Tran T, Hung P, Laucirica R, et al. The clinical significance of thickened gastric folds found on upper gastrointestinal series. J Clin Gastroenterol 2002; 35:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/43\">",
"      Yamada M, Sumazaki R, Adachi H, et al. Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Eur J Pediatr 1997; 156:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/44\">",
"      Watanabe K, Beinborn M, Nagamatsu S, et al. M&eacute;n&eacute;trier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity. Scand J Gastroenterol 2005; 40:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/45\">",
"      Ishikawa T, Ando T, Obayashi H, et al. Helicobacter pylori isolated from a patient with M&eacute;n&eacute;trier's disease increases hepatocyte growth factor mRNA expression in gastric fibroblasts: comparison with Helicobacter pylori isolated from other gastric diseases. Dig Dis Sci 2008; 53:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/46\">",
"      Gin&egrave;s A, Pellise M, Fern&aacute;ndez-Esparrach G, et al. Endoscopic ultrasonography in patients with large gastric folds at endoscopy and biopsies negative for malignancy: predictors of malignant disease and clinical impact. Am J Gastroenterol 2006; 101:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2984/abstract/47\">",
"      Kindblom LG, Angervall L, Santesson B, Selander S. Cronkhite-Canada syndrome. Case report. Cancer 1977; 39:2651.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 34 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2984=[""].join("\n");
var outline_f2_58_2984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HYPERPLASTIC GASTROPATHIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      M&eacute;n&eacute;trier's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Zollinger-Ellison syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LARGE GASTRIC FOLDS ASSOCIATED WITH OTHER CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Helicobacter pylori gastritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/34\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/34|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40533\" title=\"picture 1\">",
"      Menetriers disease Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/57/14231\" title=\"picture 2\">",
"      Lymphocytic gastritis Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=related_link\">",
"      Acute and chronic gastritis due to Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/19/2361?source=related_link\">",
"      Gastric polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=related_link\">",
"      Gastrointestinal sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=related_link\">",
"      Metaplastic (chronic) atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_58_2985="Overview of medical care of the liver transplant recipient";
var content_f2_58_2985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of medical care of the liver transplant recipient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/58/2985/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2985/contributors\">",
"     Paul J Gaglio, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2985/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/58/2985/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2985/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/58/2985/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2985/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/58/2985/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 12, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation is the treatment of choice for appropriately selected patients with end-stage liver disease. Improved long-term survival has been associated with an expansion in the number of patients being cared for outside of a transplant center, requiring familiarity in recognizing and managing complications in this patient population. These include long-term complications of immunosuppression, infections, neoplasia, recurrence of the primary disease for which liver transplantation was indicated, and finally, the challenge of \"health maintenance.\" Satisfactory quality of life up to 30 years after transplantation has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/1\">",
"     1",
"    </a>",
"    ]. However, issues related to recurrent disease and post-transplant problems (such as osteoporosis) can have an important impact on physical functioning, emphasizing the need for long-term care [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The types of complications observed after liver transplantation vary over time. Complications occurring early after transplant are mainly related to the technical aspects of the procedure. By contrast, after the first postoperative days and beyond, the nature and variety of complications change. As a general rule (perhaps overly simplistic), complications can be categorized according to the \"the rule of two's,\" ie, post-transplant complications that occur in the first two days, first two weeks, first two months, and first two years from the date of transplantation.",
"   </p>",
"   <p>",
"    This topic review will focus on the recognition and management of \"long-term\" complications, which are anticipated to occur during a time frame when the patient is being cared for by a primary care clinician or gastroenterologist. More detailed discussions on some of these areas are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link\">",
"     \"Infectious complications in liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23273?source=see_link\">",
"     \"Dermatologic problems in patients who have undergone liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF IMMUNOSUPPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cornerstone to post-transplantation management is the ability to prevent rejection of the transplanted liver. Strategies to prevent both acute and chronic rejection are predicated on understanding how recognition of the newly engrafted liver as \"foreign\" occurs and how immune-mediated injury can be modulated, while at the same time minimizing the risks associated with immunosuppression.",
"   </p>",
"   <p>",
"    The most common immunosuppressive medications used in liver transplant recipients and their side effects are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef67917 \" href=\"UTD.htm?38/60/39884\">",
"     table 1",
"    </a>",
"    ). Unfortunately, all immunosuppressive therapy is associated with undesired effects, the spectrum of which vary and in some cases overlap.",
"   </p>",
"   <p>",
"    As a general rule, most transplant centers use either two or three agents to prevent allograft rejection in the immediate post-transplant period. This typically involves a combination of a calcineurin inhibitor (CNI) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , a second agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or less commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and a glucocorticoid such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . As patients achieve adequate liver function and remain free from rejection beyond six months post-transplantation, ongoing immunosuppression can often be with monotherapy, usually with a CNI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are used as standard initial immunosuppression in patients undergoing liver transplantation. However, they are associated with significant side effects, including hypertension, dyslipidemia, glucose intolerance, infection, bone abnormalities, peptic ulcers, and psychiatric disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, most transplant centers attempt to taper and discontinue glucocorticoids within the first six months to one year following transplantation, while maintaining adequate levels of a CNI. This strategy may be altered in patients who undergo liver transplantation secondary to an immune-mediated disorder such as autoimmune hepatitis, primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) since there is a greater risk of immune mediated graft rejection associated with these diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/2\">",
"     2",
"    </a>",
"    ]. In these patients, long-term low dose corticosteroids are continued with a CNI, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    replace corticosteroids and a CNI is continued. In addition, many transplant centers have adopted policies to either rapidly taper or completely avoid any glucocorticoids; this strategy is used most commonly in HCV infected patients due to the perceived deleterious effect of steroids on HCV recurrence (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-cell activation is required to recognize foreign antigens. This process is modulated by multiple cytokines, including IL-2. Cyclosporin (CYA) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (TAC) bind to intracellular receptors; these complexes inactivate calcineurin and block T-cell signaling. Both CYA and TAC are effective in reducing acute allograft rejection in liver transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major adverse events associated with both CYA and TAC include hypertension, renal insufficiency, and neurologic complications such as tremor, seizures, and paresthesias. Multiple studies have found that obesity, hyperlipidemia, hirsutism, and gingival hyperplasia occur more commonly in liver transplant recipients who receive CYA, while a higher rate of insulin resistance and diarrhea is seen in such patients who receive TAC [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inconsistent absorption of standard CYA seen in the past has been resolved via the use of a microemulsified formulation (eg, Neoral), which allows more consistent blood levels. Despite their side effects, CNIs retain a central role in post-transplant immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Azathioprine and MMF",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (AZA) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) prevent the expansion of activated T cells and B cells which induce immune-mediated injury. AZA, a purine analogue, is metabolized in the liver to its active compound, 6-mercaptopurine, which inhibits adenosine and guanine production, thereby inhibiting DNA and RNA synthesis in rapidly proliferating T cells. MMF is a potent noncompetitive inhibitor of inosine monophosphate dehydrogenase (IMPDH), an enzyme necessary for the synthesis of guanine, a purine nucleotide.",
"   </p>",
"   <p>",
"    Randomized controlled trials have demonstrated that MMF is more effective than AZA at reducing the incidence of acute cellular rejection in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/2\">",
"     2",
"    </a>",
"    ]. MMF may also reduce the incidence of chronic rejection by inhibiting the proliferation of B lymphocytes. Many transplant centers use a combination of a CNI with either MMF or, less commonly, AZA during the first six months after transplantation.",
"   </p>",
"   <p>",
"    The major toxicities associated with MMF or AZA are bone marrow suppression manifested as leukopenia, anemia, and thrombocytopenia. MMF has been associated with a greater incidence of dyspepsia, peptic ulcers, and diarrhea when compared to AZA, while pancreatitis can occur in individuals taking AZA. These side effects are modulated by dose reduction or discontinuation, and by the use of proton pump inhibitors to minimize dyspepsia and peptic ulcers in individuals receiving MMF.",
"   </p>",
"   <p>",
"    An enteric-coated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    sodium preparation has been approved for use in renal transplantation. Several studies have reported that renal transplant patients who experienced GI intolerance to standard MMF had fewer GI symptoms when switched to enteric-coated mycophenolate sodium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .) Similar findings have been reported in liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/4\">",
"     4",
"    </a>",
"    ]. By contrast, comparative trials in unselected patients found no difference in GI tolerability between enteric-coated and non-enteric coated preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    (rapamycin, RAPA) and its derivative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    achieve their immunosuppressive effect by inhibiting mTOR (mammalian target of rapamycin). Inhibition of mTOR diminishes intracellular signaling distal to the IL-2 receptor and prevents T-cell replication. In addition, because mTOR regulates cell growth and angiogenesis, mTOR inhibition may have a role in treating or modulating growth of various cancers including hepatocellular carcinoma (HCC). (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Hepatocellular carcinoma'",
"    </a>",
"    below.) Since the lymphoproliferative pathways inhibited by RAPA and everolimus are distinct from those affected by CNIs, these agents may be used in combination with CNIs to achieve a synergistic effect.",
"   </p>",
"   <p>",
"    RAPA is used by many centers as part of a renal sparing protocol either in place of or as a substitute for a calcineurin inhibitor (",
"    <a class=\"graphic graphic_table graphicRef67917 \" href=\"UTD.htm?38/60/39884\">",
"     table 1",
"    </a>",
"    ). However, toxicity is a concern:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukopenia, thrombocytopenia, and hyperlipidemia are the principal toxicities associated with RAPA and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Hepatic arterial thrombosis has been reported in patients who received RAPA in the weeks immediately following liver transplantation, an effect possibly related to choice of dosing regimens including the use of a loading dose [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several investigators have noted problems with wound-healing in patients who received RAPA, potentially due to impairment of granulation mediated by inhibition of transforming growth factor-beta [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preliminary observations suggest a lower rate of hepatocellular carcinoma recurrence in patients treated with RAPA [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/8\">",
"       8",
"      </a>",
"      ]. Several prospective studies are ongoing that are designed to elucidate the effect of mTOR inhibitors on HCC growth and recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF COMPLICATIONS OF IMMUNOSUPPRESSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is common following liver transplantation, affecting up to 15 percent of patients, although strategies to minimize dosing of CNIs have reduced the incidence. Multiple factors can contribute to the rise in blood pressure, including CNIs, corticosteroids, renal insufficiency, and obesity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link&amp;anchor=H3#H3\">",
"     \"Long-term management of adult liver transplant recipients\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most transplant centers approach hypertension with a stepwise approach including limiting salt intake, assessing serum levels of CNI and modulating CNI dose if the level is inappropriately elevated. If antihypertensive medications are required, we suggest initiating therapy with a calcium channel blocker;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    , are preferred as first-line agents since they are long-acting, minimally interact with CNIs, and have limited side effects.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     Hydrochlorothiazide",
"    </a>",
"    is not used as primary therapy for HTN due to concerns related to the potential to exacerbate electrolyte disturbances and dyslipidemias induced by calcineurin inhibitors. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Calcineurin inhibitors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\", section on 'Hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If calcium channel blockers are not effective, we suggest the addition or substitution of a beta-blocker such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    . An angiotensin-converting enzyme (ACE) inhibitor, or angtioensin-2 receptor blocker (ARB) can also be used in patients whose HTN is difficult to control but they may have an untoward effect on renal function and induce hyperkalemia, and should therefore be used with caution. Pharmacologic agents to treat HTN, their doses, and side effects are listed in table 2 (",
"    <a class=\"graphic graphic_table graphicRef81578 \" href=\"UTD.htm?5/36/5708\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased cholesterol and triglyceride levels occur commonly after liver transplantation. Risk factors for hyperlipidemia include the effects of commonly used pharmacologic agents after transplantation, such as CNIs, corticosteroids, and RAPA. In addition, obesity either prior to or following transplantation is linked to postoperative abnormalities in cholesterol and triglycerides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss, adoption of a low fat diet, and exercise are valuable to treat abnormalities in lipid metabolism. In addition, rapid tapering and minimization of overall corticosteroid exposure can be helpful.",
"   </p>",
"   <p>",
"    Many investigators have discussed the potential benefit of altering CNIs after liver transplantation in patients with hyperlipidemia; TAC has been reported to be associated with a decreased incidence of cholesterol and lipid abnormalities when compared to CSA, and conversion from CSA to TAC may improve hyperlipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, statin cholesterol-lowering agents are safe and effective in decreasing serum total and low-density lipoprotein cholesterol, without having an impact on CNI levels [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/10\">",
"     10",
"    </a>",
"    ]. As in any patient treated with a statin, careful attention and recognition of serum aminotransferase elevation is critical. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of diabetes post-liver transplantation ranges from 13 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Diabetes has been associated with an increased rate of cardiac, neurologic and neuropsychiatric complications, infections, and interestingly, a higher rate of acute rejection in the post-transplantation period when compared to patients without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the United Network of Organ Sharing (UNOS) database indicated that cryptogenic cirrhosis, hypertension, and coronary artery disease were significantly more common following liver transplantation in patients with type 1 and 2 diabetes compared to patients without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/13\">",
"     13",
"    </a>",
"    ]. Five-year patient and graft survivals by Kaplan&ndash;Meier analysis were significantly lower for type 1 compared with type 2 diabetes or those without diabetes.",
"   </p>",
"   <p>",
"    A long-term follow-up study in over 600 patients found that patients with new onset diabetes post-liver transplantation had a significantly higher rate of death due to infection, as well as graft failure due to chronic rejection and late onset hepatic artery thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for post-transplantation diabetes include immunosuppression, particularly the requirement for prolonged or high dose corticosteroids, use of CNIs, lack of exercise, obesity, and increased caloric intake. An interesting observation is the increased incidence of new onset diabetes following transplantation in patients with hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of diabetes post-transplantation includes standard medical and nutritional therapy, including limiting caloric intake, an appropriate diet with weight loss, and the initiation of pharmacologic agents for treatment of diabetes including oral hypoglycemics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insulin as necessary. In addition, modulating immunosuppression including lowering or stopping glucocorticoids may be of benefit. The incidence of diabetes seems to be lower in patients treated with CYA compared to TAC, even when controlling for dose, exposure, and glucocorticoid use [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, many transplant centers recommend transition for TAC to CYA in patients with difficult to control diabetes following liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of obesity, defined as a body mass index greater than 30",
"    <span class=\"nowrap\">",
"     kg/m(2),",
"    </span>",
"    following liver transplantation is as high as 40 percent. Various factors, including prolonged use of glucocorticoids, the choices of immunosuppression, pretransplant obesity, and nonadherence to recommendations related to diet and exercise have been considered causative.",
"   </p>",
"   <p>",
"    A contentious issue in transplantation is the assessment of how \"safe\" liver transplantation is in obese patients. Data regarding long-term outcomes in obese patients who undergo liver transplantation show conflicting results. A review of the UNOS database found that, after adjusting for confounding variables, patient and graft survival at one month and one, two, and five years postoperatively were not significantly different when comparing obese to nonobese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/16\">",
"     16",
"    </a>",
"    ]. However, when post-transplant survival in patients with morbid obesity was analyzed using the same database, primary graft nonfunction, as well as immediate, one- and two-year mortality, was significantly higher in the morbidly obese group, and five-year mortality was significantly higher in both severely and morbidly obese patients, mainly due to adverse cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/17\">",
"     17",
"    </a>",
"    ]. Similar findings were reported in a later study of 21,674 liver transplant recipients in which a BMI &gt;35",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    was a predictor of post-transplantation mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, a study analyzing outcomes in over 700 patients found that BMI had no effect on patient or graft survival, the incidence of acute graft rejection, major surgical complications or length of hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/19\">",
"     19",
"    </a>",
"    ]. Despite these conflicting observations, many transplant centers either exclude patients with morbid obesity from consideration for transplantation or encourage weight loss prior to transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of obesity both pre- and post-liver transplantation is unfortunately difficult. Many centers adopt a policy of minimizing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rapidly tapering glucocorticoids, and encouraging exercise and limiting caloric intake. Several investigators have studied the effect of changing immunosuppression (substituting TAC for CYA preparations) since there is evidence that rates of obesity post-transplantation are greater in patients treated with CYA preparations compared to TAC, even when controlling for the effect of glucocorticoid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/20\">",
"     20",
"    </a>",
"    ]. Several small studies have described successful bariatric surgery using an adjustable gastric band placed during liver transplantation, confirming the feasibility of surgical modalities to control obesity in liver transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the incidence of obesity, diabetes, hypertension, and hypercholesterolemia is increased following liver transplantation, it is not surprising that coronary heart disease is also common. Indeed, when excluding recurrent disease, graft loss due to technical complications, and de novo malignancy, coronary heart disease represents the most common cause of death post-liver transplantation. Liver allograft recipients have a greater risk of cardiovascular deaths and ischemic events than an age- and sex-matched population of nontransplanted patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/22\">",
"     22",
"    </a>",
"    ], and cardiac complications are common after liver transplantation, representing the most common cause of death when excluding infection or graft related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, appropriately identifying and treating patients with atherosclerotic heart disease before liver transplantation is important [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with risk factors should undergo extensive pretransplantation evaluation, which includes a cardiac stress test",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac catheterization. An analysis of 161 patients who underwent cardiac catheterization as part of their liver transplantation evaluation revealed a significant incidence of coronary artery disease, particularly in patients with evidence of one or more cardiac risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with advanced heart disease not amenable to interventional therapy or with poor cardiac function should be deemed noncandidates for liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in any patient with cardiovascular disease, modification of risk factors both before and after liver transplantation is essential to maximize outcomes. Thus, treatment and prevention of obesity, hyperlipidemia, diabetes, and hypertension are priorities. At present, no clear guidelines exist related to invasive modalities (coronary angiography) or noninvasive modalities (cardiac stress testing) to prospectively assess cardiac function and coronary artery patency following liver transplantation. At our centers, we routinely recommend adenosine stress testing every three years in patients with risks for coronary artery disease, or more often in patients with preexisting coronary artery disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Renal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant source of morbidity and mortality following liver transplantation is renal failure. Renal impairment is common post-liver transplantation. In an illustrative study, renal failure developed in 15, 18, and 25 percent of patients at 3, 5, and 10 years respectively post-liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/26\">",
"     26",
"    </a>",
"    ]. Factors associated with the development of end stage renal disease following liver transplantation include a higher preoperative serum creatinine level, hepatorenal syndrome, requirement for dialysis in the first three months postoperatively, elevated serum creatinine at one year post-transplantation, and HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34250?source=see_link\">",
"     \"Renal function and nonrenal solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy of renal insufficiency following liver transplantation includes a thorough search for reversible factors including exposure to potentially nephrotoxic medications including ACE inhibitors or A2RBs, nonsteroidal antiinflammatory medications, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . Renal insufficiency can be minimized by early and aggressive control of diabetes and hypertension, and by appropriately adjusting CNI dose if blood levels are inappropriately elevated. It has been well established that CNIs are associated with nephrotoxicity via multiple mechanisms including impairment of renal blood flow, and parenchymal renal injury, which may unfortunately lead to permanent renal dysfunction.",
"   </p>",
"   <p>",
"    An alternative approach to diminishing CNI exposure to improve renal function is withdrawal and substitution of an alternative agent such as MMF or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    , which are associated with a lower risk of renal injury. This strategy, particularly when used prior to irreversible renal impairment may result in a significant decrease in the mean values of serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. However, immunosuppression with MMF or Sirolimus monotherapy may be associated with an increased risk of acute rejection, requiring vigilance to recognize and appropriately treat this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OSTEOPOROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is common, particularly in patients with end-stage liver disease due to cholestatic disorders such as PBC and PSC. Immunosuppressive therapy after transplant induces rapid bone loss, which may be associated with a significant rate of osteoporosis and bone fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An approach to treatment and prevention of osteoporosis is presented separately. We generally assess bone mineral density before transplantation and repeat it annually after transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CHRONIC REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute rejection usually occurs within the first two weeks to two months post-transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37319?source=see_link\">",
"     \"Diagnosis of acute cellular rejection in liver transplantation\"",
"    </a>",
"    .) Chronic allograft rejection, also termed \"vanishing bile duct syndrome\", can occur months to years after liver transplantation.",
"   </p>",
"   <p>",
"    As a general rule, early chronic rejection manifests as abnormalities in serum transaminases (AST, ALT), bilirubin, and alkaline phosphatase. Untreated chronic rejection, particularly when associated with bile duct loss, can be associated with pruritus and jaundice. Histologic findings supportive of chronic rejection include bile duct atrophy affecting the majority of bile ducts, with or without bile duct loss, and obliterative arteriopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    venopathy in large branches of the hepatic artery or portal vein [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/31\">",
"     31",
"    </a>",
"    ]. Risk factors for chronic rejection include transplantation for primary sclerosing cholangitis or primary biliary cirrhosis, human leukocyte antigen mismatch between donor and recipient, and CMV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic rejection is a harbinger of poor outcomes; altering immunosuppression is rarely associated with improvement, often resulting in the requirement for retransplantation. When a patient with previously stable serum aminotransferases, bilirubin and alkaline phosphatase develops abnormalities in these lab parameters, prompt referral to the transplant center is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As long-term survival rates in patients who undergo liver transplantation have improved, there has been a concomitant increase in late complications including malignancy. These may be de novo neoplasia, or a recurrence of cancers detected prior to liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early experience with liver transplantation in the setting of hepatocellular carcinoma (HCC) was associated with a recurrence rate of up to 80 percent and dismal long-term survival. This resulted in HCC being considered a contraindication to liver transplantation. However, better patient selection has permitted identification of patients who have a good prognosis with transplantation. Patients with limited HCC (one solitary lesion &lt;5 cm or three lesions each &lt;3 cm) have excellent long-term outcomes, with a five-year survival rate of 70 percent and a recurrence rate below 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/32\">",
"     32",
"    </a>",
"    ]. Many transplant centers use these criteria (sometimes referred to as the \"Milan\" or \"Mazzaferro\" criteria) to determine candidacy for transplantation in patients with HCC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=see_link\">",
"     \"Liver transplantation for hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cutaneous malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin cancer is the most common malignancy occurring after solid organ transplantation, related to sun exposure, tobacco consumption, and immunosuppression. Basal cell and squamous cell carcinoma as well as melanoma have been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23273?source=see_link\">",
"     \"Dermatologic problems in patients who have undergone liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;De novo malignancies after transplantation are common. In a retrospective analysis of over 500 patients, the incidence of de novo malignancies was 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/33\">",
"     33",
"    </a>",
"    ]. Skin cancers were the most common, but gastrointestinal, oropharyngeal, and post-transplant lymphoproliferative disease also occurred. Acute rejection and, thus, the requirement for bolus steroids and higher overall rate of immunosuppression were associated with a worse cancer prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various investigators have also noted the more rapid progression of diverse premalignant conditions following liver transplantation, including colonic adenomas, progression of Barrett's esophagus to high-grade dysplasia, and colonic dysplasia, particularly in patients with preexisting inflammatory bowel disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have undergone liver transplantation require screening for malignant and premalignant conditions. We suggest a complete annual or biannual skin exam, preferably by a dermatologist, and an annual mammogram, Pap smear or prostate-specific antigen in individuals of the appropriate sex over age 40, and a colonoscopy every three years or more frequently if clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RECURRENCE OF PRIMARY DISEASE FOLLOWING LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major challenge to most patients following liver transplantation is recurrence of the primary disease that caused the original liver injury. Diseases that do not recur following liver transplantation include congenital anatomic anomalies (biliary atresia, polycystic liver disease, Caroli's disease, Alagille's syndrome, congenital hepatic fibrosis) and metabolic diseases (Wilson's disease, alpha-1 antitrypsin deficiency). However, all other causes of liver disease, including primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, nonalcoholic fatty liver disease, hemochromatosis, and alcohol-associated liver disease, have recurred after liver transplantation, and can be associated with graft injury and failure.",
"   </p>",
"   <p>",
"    The disorders most commonly associated with recurrence include hepatitis B virus (HBV) and hepatitis C virus (HCV). Fortunately, recurrence of HBV after liver transplantation can be prevented by administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"     hepatitis B immune globulin",
"    </a>",
"    at the time of transplantation and at regular intervals thereafter, in combination with antivirals such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    . Strategies to minimize or eliminate the use of hepatitis B immune globulin are evolving, including the use of \"combination\" therapy with a nucleotide inhibitor (tenofovir or adefovir) and a nucleoside (lamivudine, entecavir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By contrast, HCV recurrence following liver transplantation represents a significant source of morbidity and mortality. HCV viremia and histologic injury following transplantation is essentially universal. Although histological injury in the allograft due to HCV is common, disease progression after the development of hepatitis is variable, with some patients experiencing indolent disease and others rapidly progressing to cirrhosis and liver failure. Treatment for recurrent HCV after transplant is limited by toxicity, although in some patients it may be possible to achieve a sustained virologic response with peginterferon alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=see_link\">",
"     \"Liver transplantation for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various immunosuppression strategies have been evaluated for their influence on HCV recurrence. There are convincing data that bolus doses of glucocorticoids given for rejection treatment have a negative impact on HCV recurrence, providing the rationale for clinical trials of corticosteroid-free maintenance immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interim, one-year report of one such study described outcomes of a corticosteroid-free regimen involving daclizumab,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and MMF, which was compared to tacrolimus and glucocorticoids, or tacrolimus, glucocorticoids, and MMF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/35\">",
"     35",
"    </a>",
"    ]. Although decreased acute rejection was observed in the group receiving daclizumab, tacrolimus, and MMF, patient and graft survival as well as rate of HCV recurrence did not differ significantly among treatment arms. Thus, the study supports the feasibility of steroid-free maintenance immunosuppression in HCV infected patients, but its benefit on HCV recurrence was not apparent, at least in the short term.",
"   </p>",
"   <p>",
"    Another prospective multicenter study in HCV infected transplant recipients assessed the impact of rapid steroid tapering and withdrawal within three months of transplant compared to slow tapering and withdrawal over two years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2985/abstract/36\">",
"     36",
"    </a>",
"    ]. Rapid tapering was significantly more likely to be associated with the development of advanced fibrosis suggesting that abrupt changes in glucocorticoid dosing, including boluses and rapid discontinuation, may negatively impact the natural history of chronic hepatitis C post-transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As patients progress beyond their one-year post-transplant \"anniversary,\" the role of the primary care provider in surveillance, prevention, and treatment of post-transplant complications becomes paramount.",
"   </p>",
"   <p>",
"    We suggest the following",
"    <span class=\"nowrap\">",
"     evaluations/procedures",
"    </span>",
"    in all post-transplant patients (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Biannual dental exam to survey for dental carries, abscesses, and other dental disease",
"     </li>",
"     <li>",
"      Annual chest X-ray",
"     </li>",
"     <li>",
"      Annual or biannual complete skin surveillance by a dermatologist",
"     </li>",
"     <li>",
"      Annual assessment of bone mineral density",
"     </li>",
"     <li>",
"      Annual mammography, Pap smear, or PSA testing as appropriate by gender beginning at age 40 or earlier in appropriate patients",
"     </li>",
"     <li>",
"      Annual flu vaccination",
"     </li>",
"     <li>",
"      Pneumovax every three years",
"     </li>",
"     <li>",
"      Biannual assessment for insulin resistance via hemoglobin A1C determination and assessment for hyperlipidemia",
"     </li>",
"     <li>",
"      Colonoscopy every three years or more frequently in patients with high risk for colonic neoplasia including individuals with ulcerative colitis, colonic polyps, or family history of colonic cancer",
"     </li>",
"     <li>",
"      Monitoring of blood pressure and serum creatinine every two to three months",
"     </li>",
"     <li>",
"      Appropriate intervention as outlined above in patients with HTN, diabetes, hyperlipidemia, obesity, atherosclerotic heart disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115763708\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/1\">",
"      Desai R, Jamieson NV, Gimson AE, et al. Quality of life up to 30 years following liver transplantation. Liver Transpl 2008; 14:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/2\">",
"      Jain A, Kashyap R, Marsh W, et al. Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation 2001; 71:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/3\">",
"      Haddad EM, McAlister VC, Renouf E, et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; :CD005161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/4\">",
"      Miras M, Carballo F, Egea J, et al. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications. Transplant Proc 2007; 39:2314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/5\">",
"      Sanford M, Keating GM. Enteric-coated mycophenolate sodium: a review of its use in the prevention of renal transplant rejection. Drugs 2008; 68:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/6\">",
"      Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003; 35:193S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/7\">",
"      Mehrabi A, Fonouni H, Wente M, et al. Wound complications following kidney and liver transplantation. Clin Transplant 2006; 20 Suppl 17:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/8\">",
"      Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 2009; 9:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/9\">",
"      Manzarbeitia C, Reich DJ, Rothstein KD, et al. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients. Liver Transpl 2001; 7:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/10\">",
"      Gazi IF, Liberopoulos EN, Athyros VG, et al. Statins and solid organ transplantation. Curr Pharm Des 2006; 12:4771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/11\">",
"      John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002; 8:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/12\">",
"      Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/13\">",
"      Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002; 74:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/14\">",
"      Moon JI, Barbeito R, Faradji RN, et al. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation 2006; 82:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/15\">",
"      Chen T, Jia H, Li J, et al. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 2009; 22:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/16\">",
"      Yoo HY, Molmenti E, Thuluvath PJ. The effect of donor body mass index on primary graft nonfunction, retransplantation rate, and early graft and patient survival after liver transplantation. Liver Transpl 2003; 9:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/17\">",
"      Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/18\">",
"      Rana A, Hardy MA, Halazun KJ, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008; 8:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/19\">",
"      Fujikawa T, Fujita S, Mizuno S, et al. Clinical and financial impact of obesity on the outcome of liver transplantation. Transplant Proc 2006; 38:3612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/20\">",
"      Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001; 7:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/21\">",
"      Campsen J, Zimmerman M, Shoen J, et al. Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes Surg 2008; 18:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/22\">",
"      Johnston SD, Morris JK, Cramb R, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/23\">",
"      Fouad TR, Abdel-Razek WM, Burak KW, et al. Prediction of cardiac complications after liver transplantation. Transplantation 2009; 87:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/24\">",
"      Ehtisham J, Altieri M, Salam&eacute; E, et al. Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management. Liver Transpl 2010; 16:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/25\">",
"      Tiukinhoy-Laing SD, Rossi JS, Bayram M, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol 2006; 98:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/26\">",
"      Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/27\">",
"      Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/28\">",
"      Asfandiyar S, Abouljoud M, Kim D, et al. Influence of hepatitis C on renal function after liver transplantation. Transplant Proc 2006; 38:3643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/29\">",
"      Manzia TM, De Liguori Carino N, Orlando G, et al. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proc 2005; 37:2616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/30\">",
"      Neff GW, Montalbano M, Slapak-Green G, et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 2003; 35:3029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/31\">",
"      Banff Working Group, Demetris AJ, Adeyi O, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/32\">",
"      Parikh S, Hyman D. Hepatocellular cancer: a guide for the internist. Am J Med 2007; 120:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/33\">",
"      Baccarani U, Adani GL, Montanaro D, et al. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc 2006; 38:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/34\">",
"      Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001; 1:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/35\">",
"      Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007; 13:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2985/abstract/36\">",
"      Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007; 47:793.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4597 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2985=[""].join("\n");
var outline_f2_58_2985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPLICATIONS OF IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Azathioprine and MMF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT OF COMPLICATIONS OF IMMUNOSUPPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CHRONIC REJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cutaneous malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RECURRENCE OF PRIMARY DISEASE FOLLOWING LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115763708\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4597\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4597|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/60/39884\" title=\"table 1\">",
"      Immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/36/5708\" title=\"table 2\">",
"      Pharmacologic agents HTN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23273?source=related_link\">",
"      Dermatologic problems in patients who have undergone liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37319?source=related_link\">",
"      Diagnosis of acute cellular rejection in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=related_link\">",
"      Infectious complications in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36362?source=related_link\">",
"      Liver transplantation for hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=related_link\">",
"      Long-term management of adult liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34250?source=related_link\">",
"      Renal function and nonrenal solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_58_2986="Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease";
var content_f2_58_2986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/58/2986/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2986/contributors\">",
"     Frank G Yanowitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/58/2986/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2986/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2986/contributors\">",
"     Ami E Iskandrian, MD, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2986/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/58/2986/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/58/2986/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/58/2986/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress testing is an important modality for the evaluation of patients with known or suspected coronary heart disease (CHD). The main indications for performing a stress test for risk assessment are during initial evaluation of suspected ischemic chest pain and in patients with a significant change in cardiac symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will provide an overview of the utility of stress testing for estimation of prognosis and to guide management in patients with known or suspected CHD. The emphasis will be on stable patients with known CHD.",
"   </p>",
"   <p>",
"    The role of stress testing for the diagnosis of stable CHD, for the estimation of prognosis in patients who have had a recent acute coronary syndrome, and in the evaluation of patients with a suspected acute coronary syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H16#H16\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Stress testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link&amp;anchor=H35#H35\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\", section on 'Stress testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link&amp;anchor=H28#H28\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\", section on 'Rest and stress imaging tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRETEST PROBABILITY OF CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress testing is of clear prognostic value in patients with known CHD. Among patients with suspected CHD, stress testing for",
"    <strong>",
"     diagnosis",
"    </strong>",
"    is warranted only in those with an intermediate pretest probability of disease. Patients at high pretest probability will have a high rate of false negative tests, while those with a low pretest probability will have a high rate of false positive tests (",
"    <a class=\"graphic graphic_table graphicRef53433 \" href=\"UTD.htm?6/8/6284\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64463 \" href=\"UTD.htm?16/46/17132\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link&amp;anchor=H2#H2\">",
"     \"Stress testing for the diagnosis of coronary heart disease\", section on 'Pretest probability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, stress testing for",
"    <strong>",
"     prognosis",
"    </strong>",
"    in patients with suspected CHD should be performed in those at intermediate or high pretest probability. In these patients, stress testing can identify patients at variable degrees of mortality risk, which can be used to guide further evaluation and therapy.",
"   </p>",
"   <p>",
"    The limited value of stress testing for prognosis in patients with a low pretest probability of CHD (&le;25 percent) was illustrated in a study of 1618 such patients referred for exercise echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/5\">",
"     5",
"    </a>",
"    ]. At a median follow-up of three years, a cardiac event occurred in only 9 of 346 patients (2.6 percent) with an abnormal exercise echocardiogram. In addition, only 9 of 19 patients who had a cardiac event had an abnormal test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STRESS TESTING FOR PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major factors determine the prognosis of patients with CHD:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The amount and distribution of viable but jeopardized left ventricular myocardium",
"     </li>",
"     <li>",
"      The percentage of irreversibly scarred myocardium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latter is usually evaluated noninvasively by echocardiography or radionuclide myocardial perfusion imaging, while the former is usually assessed by clinical factors and by stress testing. Patients with a larger number of vessels involved have a worse outcome in part because of more jeopardized myocardium and in part because of a greater potential for atherosclerotic plaques to become vulnerable and rupture, producing an acute coronary syndrome or even sudden cardiac death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with stable angina, the main indications for stress testing are at initial evaluation and when there is a significant change in cardiac symptoms (",
"    <a class=\"graphic graphic_table graphicRef64807 \" href=\"UTD.htm?15/11/15548\">",
"     table 3A",
"    </a>",
"    ). Numerous studies in patients with known or suspected CHD have shown that the response to stress testing can help in risk stratification (",
"    <a class=\"graphic graphic_table graphicRef67639 \" href=\"UTD.htm?26/30/27116\">",
"     table 4",
"    </a>",
"    ), which may lead to a decision to refer the patient for revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Test options",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of stress testing modalities are available. These tests have two main features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The type of stress &mdash; Exercise, vasodilators (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      and adenosine) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"     </li>",
"     <li>",
"      The measure of induced ischemia &mdash; Evidence of ischemia may be assessed in several ways: ECG changes with electrocardiography; perfusion defects with radionuclide myocardial perfusion imaging (rMPI); and wall motion abnormalities with echocardiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree of ischemia can be graded semiquantitatively by each of these methods. Ischemia can also be localized by rMPI or echocardiography, but not by the exercise ECG. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a list of the different stress testing modalities. The data supporting the ability of the individual tests to estimate prognosis will be briefly reviewed below and are discussed in detail elsewhere in the appropriate topic reviews:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise ECG testing (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Exercise rMPI (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link&amp;anchor=H19#H19\">",
"       \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Exercise rMPI for prognosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pharmacologic stress rMPI with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      , adenosine, and, less often,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link&amp;anchor=H12#H12\">",
"       \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Prognosis of CHD'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Exercise or pharmacologic stress (mostly using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      ) echocardiography; vasodilator (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      or adenosine) echocardiography is infrequently performed because dobutamine echocardiography has a better combination of sensitivity and specificity (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"       \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Advantages of exercise stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptom-limited treadmill or bicycle exercise is the preferred form of stress because it provides the most information concerning patient symptoms, cardiovascular function, and the hemodynamic response during usual forms of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient must be able to exercise to goal levels, since failure to achieve at least 85 percent of the predicted maximal heart rate is considered inadequate if the test is otherwise negative. The inability to perform an exercise test is in itself a negative prognostic factor in patients with CHD. Thus, patients who require pharmacologic stress have a higher risk of subsequent events than those who undergo exercise testing, even if the stress test is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of variables, either alone or in combination, are associated with a worse cardiovascular outcome in patients who undergo exercise stress. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor exercise capacity (&lt;5 METs)",
"     </li>",
"     <li>",
"      Exercise-induced angina, particularly at a low workload",
"     </li>",
"     <li>",
"      Abnormally low peak systolic blood pressure (&lt;130 mmHg) or a fall in systolic blood pressure below baseline during exercise",
"     </li>",
"     <li>",
"      Chronotropic incompetence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exercise capacity or workload is an important determinant of prognosis and, in some studies of exercise testing, has been the strongest predictor of mortality and cardiovascular events, particularly in elderly persons [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Exercise capacity, which is a measure of fitness, also has prognostic value in the general population. Individuals with poor exercise capacity are at increased cardiovascular risk, while those with excellent exercise capacity are at reduced risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\", section on 'Relation to fitness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Exercise ECG testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise ECG testing is a preferred component of stress testing in most patients. In addition to the above exercise-associated above parameters, there are also a number of ECG findings that have prognostic value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=see_link\">",
"     \"Electrocardiographic changes during exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in patients with certain baseline ECG abnormalities, evidence of ischemia is obscured and the ECG component of the test cannot be interpreted. These abnormalities include preexcitation (Wolff-Parkinson-White) syndrome, more than 1 mm of ST depression at rest, and patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or with ECG criteria for left ventricular hypertrophy, even if they have less than 1 mm of baseline ST depression. In patients with baseline right bundle branch block, ECG changes in leads V1-V3 are nondiagnostic.",
"   </p>",
"   <p>",
"    Patients with one or more of these abnormalities should be tested with echocardiography or rMPI; pharmacologic stress is warranted in patients who are unable to exercise (",
"    <a class=\"graphic graphic_algorithm graphicRef71324 \" href=\"UTD.htm?26/52/27470\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef64807 graphicRef74428 \" href=\"UTD.htm?31/62/32749\">",
"     table 3A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stress testing in patients with LBBB or with a paced ventricular rhythm is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Duke treadmill score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treadmill scores have been derived in an attempt to more effectively estimate prognosis after exercise ECG testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most popular validated treadmill score comes from Duke University and is based upon data from 2758 consecutive patients seen from 1969 through 1980 with a median age of 49 who had chest pain and underwent both exercise treadmill testing and coronary angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/10\">",
"     10",
"    </a>",
"    ]. Testing in a subsequent sample of 467 patients seen from 1984 through 1990 was used to validate the results.",
"   </p>",
"   <p>",
"    There were a number of important",
"    <strong>",
"     exclusions",
"    </strong>",
"    in this study. These included patients who were asymptomatic, had significant valvular or congenital heart disease, an uninterpretable ECG, a surgical or percutaneous revascularization procedure performed in the past or within three months after the exercise test, or a recent myocardial infarction.",
"   </p>",
"   <p>",
"    The Duke treadmill score uses three exercise parameters:",
"   </p>",
"   <p>",
"    Duke prognostic treadmill score =",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Exercise time (minutes based on the Bruce protocol) -",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(5 x maximum ST segment deviation in mm) - (4 x exercise angina [0 = none,",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;1 = nonlimiting, and 2 = exercise limiting])",
"   </p>",
"   <p>",
"    Patients are classified as low, moderate, or high risk according to the score:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low-risk &ndash; score &ge;+5",
"     </li>",
"     <li>",
"      Moderate-risk &mdash; score from &ndash; 10 to +4",
"     </li>",
"     <li>",
"      High-risk &ndash; score &le;-11",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The utility of the Duke treadmill score was illustrated in an analysis of the original Duke cohort of 2758 medically treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/11\">",
"     11",
"    </a>",
"    ]. The following findings were noted in the different risk groups (",
"    <a class=\"graphic graphic_figure graphicRef59562 \" href=\"UTD.htm?34/10/34989\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 36 percent of patients categorized as low-risk, 60 percent had no coronary stenosis &ge;75 percent, 16 percent had single vessel disease, and 9 percent had three vessel or left main disease; five-year survival was above 97 percent.",
"     </li>",
"     <li>",
"      Among the 9 percent of patients categorized as high-risk, 74 percent had three vessel or left main disease and five-year survival was 65 percent.",
"     </li>",
"     <li>",
"      Among the 55 percent of patients categorized as moderate-risk, the frequency of three vessel or left main disease (31 percent) and five-year survival (90 percent) were intermediate between the other two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognosis was better in women than men but the Duke treadmill score did not effectively risk stratify women, which may in part reflect the young age (median 49 years) of the tested patients (",
"    <a class=\"graphic graphic_figure graphicRef79590 \" href=\"UTD.htm?14/55/15230\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/12\">",
"     12",
"    </a>",
"    ]. The Duke treadmill score did not identify a truly low risk group in older adults in whom workload may be the most important predictor of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H14#H14\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Specific patient groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Duke treadmill score added independent prognostic information to that provided by clinical data, coronary anatomy, and left ventricular function. As an example, subset analysis in the original study revealed that, among patients with three vessel disease, those with an abnormal exercise score had a five year survival rate of 67 percent compared with 93 percent for those with a normal exercise score [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible limitation to the survival rates in studies utilizing the Duke treadmill score is that the results were obtained before the use of current medical therapies that significantly improve patient outcomes such as statin therapy to appropriate LDL-cholesterol goals and perhaps lower blood pressure goals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adverse predictors with imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who cannot exercise and require pharmacologic stress rMPI, the following findings are associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large defect size (&gt;20 percent of the left ventricle)",
"     </li>",
"     <li>",
"      Defects in more than one coronary artery territory, suggestive of multivessel CHD",
"     </li>",
"     <li>",
"      Large number of nonreversible defects",
"     </li>",
"     <li>",
"      Transient or fixed left ventricular cavity dilatation",
"     </li>",
"     <li>",
"      Resting left ventricular ejection fraction &lt;40 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients who can exercise but undergo rMPI because of the ECG abnormalities noted above that can interfere with interpretation, there is an additional imaging finding indicative of higher risk: increased lung uptake of thallium or sestamibi, which is a marker of exercise-induced left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link&amp;anchor=H19#H19\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Exercise rMPI for prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link&amp;anchor=H12#H12\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Prognosis of CHD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with undergo exercise or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography, the main prognostic echocardiographic variable is the extent and severity of induced ischemia, as manifested by wall motion abnormalities (",
"    <a class=\"graphic graphic_figure graphicRef68442 \" href=\"UTD.htm?4/62/5102\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Exercise ECG testing with imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;At a given Duke treadmill score, the prognosis can be further stratified by concurrently performed exercise echocardiography or rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. As an example, the prognostic utility of exercise echocardiography combined with exercise ECG testing was examined in a study of 5375 patients with known or suspected CHD who were followed for 5.5 years; a normal exercise echocardiography test was associated with a low risk of death, while the presence and extent of wall motion abnormalities were independent prognostic predictors that added incremental value to the Duke treadmill score (",
"    <a class=\"graphic graphic_figure graphicRef68442 \" href=\"UTD.htm?4/62/5102\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with a low risk Duke treadmill score, the yearly mortality in those with a normal rest echo study or evidence of disease in a single or multivessel territory was 0.7, 1.8, and 3 percent, respectively. However, although multivessel territory disease on echocardiography was associated with increased risk, it was present in only 1.4 percent of patients with a low risk Duke treadmill score.",
"     </li>",
"     <li>",
"      Among patients with a moderate risk Duke treadmill score, the yearly mortality in the three echocardiographic groups was 2.4, 3.7, and 7 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients with a high risk Duke treadmill score, the yearly mortality in the three echocardiographic groups was 4.6, 5, and 12 percent, respectively.",
"     </li>",
"     <li>",
"      Among patients with a normal echocardiographic study, the yearly mortality was 1 percent overall, and 0.7, 2.4, and 4.6 percent, respectively, in patients with a low, moderate, and high risk Duke treadmill score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An overall cardiac event rate &le;1 percent with a normal stress test has also been noted in other reports of patients undergoing exercise echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/19\">",
"     19",
"    </a>",
"    ] and in patients with normal findings on pharmacologic stress echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/16\">",
"     16",
"    </a>",
"    ] or stress rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/17,20,21\">",
"     17,20,21",
"    </a>",
"    ]. One study, for example, followed 4649 subjects with known or suspected CHD who were at intermediate risk by the Duke treadmill score (-10 to +4) and had a normal or near-normal rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/17\">",
"     17",
"    </a>",
"    ]. Cardiovascular survival and cardiac survival free of MI at seven years were 99 and 97 percent, respectively.",
"   </p>",
"   <p>",
"    Performing imaging with exercise ECG testing also adds value in patients who have undergone revascularization, increasing sensitivity and documenting both the site and extent of ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20138?source=see_link\">",
"     \"Role of stress testing after coronary revascularization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the ability to exercise and the findings on electrocardiography or imaging, clinical factors also affect prognosis. The potential importance of clinical factors was illustrated in a review of 1461 symptomatic patients who underwent exercise ECG and exercise rMPI and a low risk (&ge;+5) Duke treadmill score [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/18\">",
"     18",
"    </a>",
"    ]. A clinical score was determined by giving one point each for typical angina, a history of myocardial infarction, diabetes, insulin use, and male gender and one point for each decade over age 40; a clinical score &ge;5 denoted high risk and was present in 21 percent of patients.",
"   </p>",
"   <p>",
"    Seven year survival was 99 percent in the patients with a low risk clinical score (&lt;5), independent of whether the perfusion scan was normal, mildly abnormal, or severely abnormal. Among the minority of patients with a high risk clinical score, seven year survival was 94 percent with a normal or mildly abnormal scan and 84 percent with a severely abnormal scan. The last, relatively high risk group of 79 patients comprised 5.4 percent of the total study group.",
"   </p>",
"   <p>",
"    A history of dyspnea (\"do you experience short of breath?\") has been an adverse predictor in most [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/22-24\">",
"     22-24",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/25\">",
"     25",
"    </a>",
"    ]. Such a relationship was demonstrated in a review of almost 18,000 patients free of known cardiomyopathy or valvular disease who underwent rest and stress rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/22\">",
"     22",
"    </a>",
"    ]. At 2.7 year follow-up, the 6 percent of patients with a history of dyspnea but not chest pain had, after multivariable analysis, significant increases in cardiac and all-cause mortality compared to all other subgroups, including those with typical angina and those with or without stress-induced ischemia.",
"   </p>",
"   <p>",
"    Among the patients with dyspnea, the prognosis varied with the rMPI findings as cardiac mortality ranged from 4.2 percent with a normal rMPI to 9.5 percent with a mild defect to 17.0 to 21.4 percent with moderate to severe defects [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/23\">",
"     23",
"    </a>",
"    ]. Possible explanations for the adverse effect of dyspnea include ischemia (although the risk was still increased in patients with a normal stress rMPI), left ventricular dysfunction, and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally agree with the 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on chronic stable angina and on exercise testing for the indications for stress testing for prognosis in patients with known or suspected CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These indications were not changed in the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update on chronic angina [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three issues need to be addressed: the indications for stress testing, the choice of test, and the choice of therapy based upon the results of the test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two primary indications for stress testing for prognosis (",
"    <a class=\"graphic graphic_table graphicRef64807 \" href=\"UTD.htm?15/11/15548\">",
"     table 3A",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At the time of initial evaluation for possible angina",
"     </li>",
"     <li>",
"      After a significant change in cardiac symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testing is warranted only in patients with an intermediate or high pretest probability of CHD. An abnormal test, unless it is markedly abnormal, in patients at low pretest probability is highly likely to be a false positive (",
"    <a class=\"graphic graphic_table graphicRef64463 \" href=\"UTD.htm?16/46/17132\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pretest probability of CHD'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Stress testing is also performed in most patients who have had an acute coronary syndrome, and in symptomatic patients and selected asymptomatic patients with prior revascularization. These indications are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=see_link\">",
"     \"Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20138?source=see_link\">",
"     \"Role of stress testing after coronary revascularization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Choice of test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guidelines note that symptom-limited treadmill or bicycle exercise is the preferred form of stress in patients with known or suspected CHD because it provides the most information concerning patient symptoms, cardiovascular function, and the hemodynamic response during usual forms of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Furthermore, the inability to perform an exercise test is in itself a negative prognostic factor in patients with CHD. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Advantages of exercise stress'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     2002 ACC/AHA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to recommendations in the 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, exercise ECG testing without imaging is the preferred initial test in most patients. These recommendations were not changed in the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update on chronic angina [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are, however, two groups of patients in whom this modality should not be performed and other forms of stress testing are warranted (",
"    <a class=\"graphic graphic_algorithm graphicRef71324 \" href=\"UTD.htm?26/52/27470\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=see_link\">",
"     \"Performance of exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ECG changes at rest that can interfere with interpretation of the exercise test. These abnormalities include preexcitation (Wolff-Parkinson-White) syndrome, more than 1 mm of ST depression at rest, and patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      or with ECG criteria for left ventricular hypertrophy, even if they have less than 1 mm of baseline ST depression. LBBB or paced ventricular rhythm are other examples.",
"     </li>",
"     <li>",
"      Patients who are unable to exercise sufficiently due to leg claudication, arthritis, deconditioning, or associated pulmonary disease. A diagnostic test that fails to achieve at least 85 percent of the patient's predicted maximal heart rate is considered inadequate if the test is otherwise negative (ie, absence of chest discomfort or ECG findings).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on stable angina suggest the following approach to risk stratification in such patients depending upon whether the patient can or cannot exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient has an abnormal resting ECG abnormalities but can exercise, either exercise rMPI or exercise echocardiography can be performed (",
"      <a class=\"graphic graphic_table graphicRef74428 \" href=\"UTD.htm?32/46/33516\">",
"       table 3B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, exercise stress testing may be misleading in patients with LBBB in whom there is an appreciable incidence of transient defects in the anteroseptal and septal regions in the absence of a lesion within the left anterior descending coronary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/27\">",
"     27",
"    </a>",
"    ]. Stress testing in patients with LBBB or with a paced ventricular rhythm is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient cannot exercise,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      or adenosine rMPI or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography is recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stress rMPI or echocardiography are also preferred in patients who have undergone revascularization because of the significantly lower sensitivity and specificity with exercise ECG testing [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/28,29\">",
"     28,29",
"    </a>",
"    ] and the need to document both the site and extent of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1,2,30-32\">",
"     1,2,30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20138?source=see_link\">",
"     \"Role of stress testing after coronary revascularization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     ACCF/ASNC appropriateness criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, there was conflicting evidence regarding the usefulness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    efficacy of exercise testing with imaging (radionuclide myocardial perfusion imaging or echocardiography) as an initial test in patients without the above ECG abnormalities, an inability exercise to a sufficient degree, or a history of revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1,2,26\">",
"     1,2,26",
"    </a>",
"    ]. However, in 2005, the American College of Cardiology Foundation and American Society of Nuclear Cardiology",
"    <span class=\"nowrap\">",
"     (ACCF/ASNC)",
"    </span>",
"    have published appropriateness criteria for the use of radionuclide myocardial perfusion imaging during stress testing that were endorsed by the AHA [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. These criteria were developed to guide physician decision making and reimbursement policy",
"   </p>",
"   <p>",
"    Indications categorized as appropriate were broader than those outlined in the 2002 guidelines, and included the following additions to the above recommended groups [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a chest pain syndrome and an intermediate or high pretest probability of CHD, regardless of the features on the baseline ECG or their ability to exercise.",
"     </li>",
"     <li>",
"      Asymptomatic individuals with moderate CHD risk according to the Framingham risk score who have high-risk occupations (eg, airline pilots).",
"     </li>",
"     <li>",
"      Asymptomatic individuals with high CHD risk according to the Framingham score or high coronary calcium scores (Agatston score &ge;400). In such individuals with a history of prior normal rMPI studies, repeat studies at intervals of two years or more was also considered appropriate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"       \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asymptomatic individuals with known CHD, for routine reevaluation at intervals of two years or more.",
"     </li>",
"     <li>",
"      Asymptomatic individuals five or more years after CABG surgery.",
"     </li>",
"     <li>",
"      Patients with other heart conditions such as newly diagnosed heart failure with chest pain, newly diagnosed heart",
"      <span class=\"nowrap\">",
"       failure/asymptomatic",
"      </span>",
"      left ventricular dysfunction without chest pain at moderate risk for CHD (Framingham score), atrial fibrillation at high risk for CHD, or ventricular tachycardia at moderate to high risk for CHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings on stress testing can be used to determine the choice between medical therapy and revascularization in patients with stable angina. As noted above, the data upon which these recommendations are made were obtained before the use of current medical therapies that significantly improve patient outcomes such as statin therapy to appropriate LDL-cholesterol goals and perhaps lower blood pressure goals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H15#H15\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Goal blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This may be important clinically since mortality benefits from revascularization in patients with stable angina have only been demonstrated in patients with underlying left ventricular dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a large amount of myocardium supplied by the diseased vessel (eg, left main coronary artery stenosis or left main equivalent disease, three vessel disease, or two vessel disease when there is more than a 75 percent stenosis in the left anterior descending artery proximal to the first major septal artery). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'Effects on survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of chronic stable angina recommended coronary angiography in selected patients based upon symptoms, left ventricular function, and estimated risk by stress testing (",
"    <a class=\"graphic graphic_table graphicRef63658 \" href=\"UTD.htm?30/51/31548\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. The 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on exercise testing made specific estimates of risk that would warrant angiography and possible revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiography should usually be performed in patients with a yearly mortality risk of more than 4 percent per year (eg, high risk Duke treadmill score) or 2 to 3 percent per year (eg, moderate risk Duke treadmill score) in patients with left ventricular dysfunction.",
"     </li>",
"     <li>",
"      Patients with an estimated mortality of 2 to 3 percent per year without left ventricular dysfunction should undergo additional testing, either angiography or an exercise imaging study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These parameters can be used to guide management in patients at low, intermediate, and high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Low risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a low risk Duke treadmill score (&ge;+5) on exercise ECG testing or those with normal stress rMPI or stress echocardiography have an overall mortality risk of less than 1 percent per year (",
"    <a class=\"graphic graphic_figure graphicRef59562 \" href=\"UTD.htm?34/10/34989\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/11,15,16,18-20,35\">",
"     11,15,16,18-20,35",
"    </a>",
"    ]. Such patients are usually treated medically [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with a low risk Duke treadmill score, the prognosis can be further stratified by a clinical determination of risk and by the findings on concurrently performed exercise rMPI or echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. In one report, for example, the yearly mortality in patients with a low risk Duke treadmill score varied with the findings on exercise echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15\">",
"     15",
"    </a>",
"    ]. The yearly mortality in patients with a normal echocardiographic study or evidence of disease in a single or multivessel territory was 0.7, 1.8, and 3 percent, respectively.",
"   </p>",
"   <p>",
"    Despite these findings, the 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines do not recommend routine rMPI or echocardiography in patients with a low risk exercise ECG test [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/2\">",
"     2",
"    </a>",
"    ]. Although further risk stratification can be achieved, the number of patients with a low risk exercise ECG test who have multivessel abnormalities and are therefore at higher risk is very small. In the above echocardiographic study, only 44 of 3063 patients (1.4 percent) with a low risk Duke treadmill score had multivessel abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that clinical factors can identify patients with low risk treadmill scores who are at higher risk and therefore might benefit from further risk stratification with concurrent rMPI. A report cited above evaluated 1461 symptomatic patients with a low risk (&ge;+5) Duke treadmill score [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/18\">",
"     18",
"    </a>",
"    ]. A clinical score was determined by giving one point each for typical angina, a history of myocardial infarction, diabetes, insulin use, and male gender and one point for each decade over age 40; a clinical score &ge;5 denoted high risk and was present in 21 percent of patients. In this setting, rMPI was of no value in patients with a low clinical score (seven year survival 99 percent independent of whether the perfusion scan was normal, mildly abnormal, or severely abnormal). Among those with a high risk clinical score, seven year survival was 94 percent with a normal or mildly abnormal scan and 84 percent with a severely abnormal scan.",
"   </p>",
"   <p>",
"    The last, relatively high risk group of 79 patients comprised 26 percent of the patients with a high clinical score. In comparison, this high risk group comprised only 5.4 of the total study population in which the clinical score was not taken into account.",
"   </p>",
"   <p>",
"    The seven year survival of 84 percent in this high risk group reflects a mortality of approximately 2.3 percent per year. This rate is close to the rate noted above at which the 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on exercise testing recommended that angiography and possible revascularization be performed (yearly mortality risk of more than 4 percent per year as estimated from the Duke treadmill score or 2 to 3 percent per year in patients with left ventricular dysfunction) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, concurrent imaging may be considered in at least selected patients with a high clinical score.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     High risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at high risk on stress testing are typically referred for angiography (",
"    <a class=\"graphic graphic_table graphicRef63658 \" href=\"UTD.htm?30/51/31548\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/2\">",
"     2",
"    </a>",
"    ]. This general recommendation does not apply to patients with severe comorbidities that are likely to limit life expectancy or prevent revascularization (",
"    <a class=\"graphic graphic_table graphicRef64807 \" href=\"UTD.htm?15/11/15548\">",
"     table 3A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The data confirming the relatively poor outcomes in high risk patients have been described above but can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients who undergo exercise ECG testing and have a high risk Duke treadmill score (&le;-11), 74 percent in one series had three vessel or left main disease and the median five-year survival was 65 percent (mortality 7 percent per year) (",
"      <a class=\"graphic graphic_figure graphicRef59562 \" href=\"UTD.htm?34/10/34989\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/11\">",
"       11",
"      </a>",
"      ]. The addition of another test, such as exercise echocardiography, does not identify a low risk group in this population [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, long-term survival is lowest in patients with wall motion abnormalities on stress echocardiography which are extensive, involve multiple territories, or are associated with a stress-induced decrease in left ventricular ejection fraction or increase in left ventricular cavity size (",
"      <a class=\"graphic graphic_figure graphicRef68442 \" href=\"UTD.htm?4/62/5102\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef64154 \" href=\"UTD.htm?23/59/24510\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15,36-39\">",
"       15,36-39",
"      </a>",
"      ] and in patients with large defects on stress rMPI (",
"      <a class=\"graphic graphic_figure graphicRef64441 \" href=\"UTD.htm?19/40/20110\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef59154 \" href=\"UTD.htm?24/24/24962\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/20,40\">",
"       20,40",
"      </a>",
"      ]. The Duke treadmill score can further risk stratify patients with multivessel disease but the yearly mortality remains appreciable even in patients with a low risk score (3 percent in one study) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Intermediate risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at intermediate risk on stress testing (estimated mortality 2 to 3 percent per year) should be referred for angiography if they have impaired left ventricular function, and either angiography or an imaging study (if only exercise ECG testing has been performed) in the absence of left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical estimate of risk, as described above, may affect the latter decision [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise rMPI, for example, can identify patients with an intermediate risk Duke treadmill score (-10 to +4) who are at low cardiac risk and can be managed medically. This was illustrated in a study of 4649 patients with known or suspected CHD who had an intermediate risk Duke treadmill score and a normal or near-normal rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/17\">",
"     17",
"    </a>",
"    ]. Cardiovascular survival and cardiac survival free of MI at seven years were 99 and 97 percent, respectively. The risk was greater in patients with cardiomegaly (seven-year cardiac survival 89 percent).",
"   </p>",
"   <p>",
"    Further risk stratification can also be achieved when exercise ECG testing is combined with exercise echocardiography. The magnitude of this effect was illustrated in a study of 5375 patients with known or suspected CHD who were followed for 5.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/15\">",
"     15",
"    </a>",
"    ]. Among the 2023 patients with an intermediate risk Duke treadmill score, the yearly mortality was 2.4 percent in the 62 percent of patients with normal left ventricular function at rest; and 3.7, and 7 percent, respectively, in those with abnormal resting left ventricular function and exercise-induced abnormalities in a single or multivessel territory.",
"   </p>",
"   <p>",
"    Similar findings have been noted in other studies in which the extent of ischemia on exercise echocardiography provides prognostic information that is incremental to clinical information, exercise ECG testing, and resting echocardiography. This benefit has been noted in older adults, both women and men, and patients who have undergone coronary artery bypass graft surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?2/58/2986/abstract/38,39,41\">",
"     38,39,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics\". The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       \"Patient information: ECG and stress test (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=see_link\">",
"       \"Patient information: Nuclear heart testing (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/1\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/3\">",
"      Diamond GA, Forrester JS. Analysis of probability as an aid in the clinical diagnosis of coronary-artery disease. N Engl J Med 1979; 300:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/4\">",
"      Weiner DA, Ryan TJ, McCabe CH, et al. Exercise stress testing. Correlations among history of angina, ST-segment response and prevalence of coronary-artery disease in the Coronary Artery Surgery Study (CASS). N Engl J Med 1979; 301:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/5\">",
"      Elhendy A, Shub C, McCully RB, et al. Exercise echocardiography for the prognostic stratification of patients with low pretest probability of coronary artery disease. Am J Med 2001; 111:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/6\">",
"      Navare SM, Mather JF, Shaw LJ, et al. Comparison of risk stratification with pharmacologic and exercise stress myocardial perfusion imaging: a meta-analysis. J Nucl Cardiol 2004; 11:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/7\">",
"      Myers J, Prakash M, Froelicher V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/8\">",
"      Goraya TY, Jacobsen SJ, Pellikka PA, et al. Prognostic value of treadmill exercise testing in elderly persons. Ann Intern Med 2000; 132:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/9\">",
"      Spin JM, Prakash M, Froelicher VF, et al. The prognostic value of exercise testing in elderly men. Am J Med 2002; 112:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/10\">",
"      Mark DB, Hlatky MA, Harrell FE Jr, et al. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med 1987; 106:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/11\">",
"      Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation 1998; 98:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/12\">",
"      Alexander KP, Shaw LJ, Shaw LK, et al. Value of exercise treadmill testing in women. J Am Coll Cardiol 1998; 32:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/13\">",
"      Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol 2004; 11:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/14\">",
"      Leslie WD, Tully SA, Yogendran MS, et al. Prognostic value of lung sestamibi uptake in myocardial perfusion imaging of patients with known or suspected coronary artery disease. J Am Coll Cardiol 2005; 45:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/15\">",
"      Marwick TH, Case C, Vasey C, et al. Prediction of mortality by exercise echocardiography: a strategy for combination with the duke treadmill score. Circulation 2001; 103:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/16\">",
"      Sicari R, Pasanisi E, Venneri L, et al. Stress echo results predict mortality: a large-scale multicenter prospective international study. J Am Coll Cardiol 2003; 41:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/17\">",
"      Gibbons RJ, Hodge DO, Berman DS, et al. Long-term outcome of patients with intermediate-risk exercise electrocardiograms who do not have myocardial perfusion defects on radionuclide imaging. Circulation 1999; 100:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/18\">",
"      Poornima IG, Miller TD, Christian TF, et al. Utility of myocardial perfusion imaging in patients with low-risk treadmill scores. J Am Coll Cardiol 2004; 43:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/19\">",
"      McCully RB, Roger VL, Mahoney DW, et al. Outcome after normal exercise echocardiography and predictors of subsequent cardiac events: follow-up of 1,325 patients. J Am Coll Cardiol 1998; 31:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/20\">",
"      Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998; 97:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/21\">",
"      Shaw LJ, Hendel R, Borges-Neto S, et al. Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. J Nucl Med 2003; 44:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/22\">",
"      Abidov A, Rozanski A, Hachamovitch R, et al. Prognostic significance of dyspnea in patients referred for cardiac stress testing. N Engl J Med 2005; 353:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/23\">",
"      Marwick TH. Dyspnea and risk in suspected coronary disease. N Engl J Med 2005; 353:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/24\">",
"      Bergeron S, Ommen SR, Bailey KR, et al. Exercise echocardiographic findings and outcome of patients referred for evaluation of dyspnea. J Am Coll Cardiol 2004; 43:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/25\">",
"      Christopher Jones R, Pothier CE, Blackstone EH, Lauer MS. Prognostic importance of presenting symptoms in patients undergoing exercise testing for evaluation of known or suspected coronary disease. Am J Med 2004; 117:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/26\">",
"      Fraker TD Jr, Fihn SD, 2002 Chronic Stable Angina Writing Committee, et al. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007; 50:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/27\">",
"      Vaduganathan P, He ZX, Raghavan C, et al. Detection of left anterior descending coronary artery stenosis in patients with left bundle branch block: exercise, adenosine or dobutamine imaging? J Am Coll Cardiol 1996; 28:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/28\">",
"      Hecht HS, Shaw RE, Chin HL, et al. Silent ischemia after coronary angioplasty: evaluation of restenosis and extent of ischemia in asymptomatic patients by tomographic thallium-201 exercise imaging and comparison with symptomatic patients. J Am Coll Cardiol 1991; 17:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/29\">",
"      Hecht HS, DeBord L, Shaw R, et al. Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1993; 71:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/30\">",
"      Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/31\">",
"      Zellweger MJ, Lewin HC, Lai S, et al. When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies. J Am Coll Cardiol 2001; 37:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/32\">",
"      Kafka H, Leach AJ, Fitzgibbon GM. Exercise echocardiography after coronary artery bypass surgery: correlation with coronary angiography. J Am Coll Cardiol 1995; 25:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/33\">",
"      Brindis RG, Douglas PS, Hendel RC, et al. ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology endorsed by the American Heart Association. J Am Coll Cardiol 2005; 46:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/34\">",
"      Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J Am Coll Cardiol 2009; 53:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/35\">",
"      Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging. A diagnostic tool comes of age. Circulation 1991; 83:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/36\">",
"      Marwick TH, Case C, Sawada S, et al. Prediction of mortality using dobutamine echocardiography. J Am Coll Cardiol 2001; 37:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/37\">",
"      Chuah SC, Pellikka PA, Roger VL, et al. Role of dobutamine stress echocardiography in predicting outcome in 860 patients with known or suspected coronary artery disease. Circulation 1998; 97:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/38\">",
"      Arruda AM, Das MK, Roger VL, et al. Prognostic value of exercise echocardiography in 2,632 patients &gt; or = 65 years of age. J Am Coll Cardiol 2001; 37:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/39\">",
"      Arruda-Olson AM, Juracan EM, Mahoney DW, et al. Prognostic value of exercise echocardiography in 5,798 patients: is there a gender difference? J Am Coll Cardiol 2002; 39:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/40\">",
"      Heller GV, Herman SD, Travin MI, et al. Independent prognostic value of intravenous dipyridamole with technetium-99m sestamibi tomographic imaging in predicting cardiac events and cardiac-related hospital admissions. J Am Coll Cardiol 1995; 26:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/58/2986/abstract/41\">",
"      Arruda AM, McCully RB, Oh JK, et al. Prognostic value of exercise echocardiography in patients after coronary artery bypass surgery. Am J Cardiol 2001; 87:1069.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1497 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2986=[""].join("\n");
var outline_f2_58_2986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRETEST PROBABILITY OF CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STRESS TESTING FOR PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Test options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Advantages of exercise stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Duke treadmill score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adverse predictors with imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Exercise ECG testing with imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Choice of test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - 2002 ACC/AHA guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - ACCF/ASNC appropriateness criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Low risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - High risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Intermediate risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1497\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1497|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/52/27470\" title=\"algorithm 1\">",
"      Choice stress test modality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1497|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/10/34989\" title=\"figure 1\">",
"      Duke Treadmill Score and survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/55/15230\" title=\"figure 2\">",
"      Duke Treadmill Score and prognosis by gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5102\" title=\"figure 3\">",
"      Stress echocardiography outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/59/24510\" title=\"figure 4\">",
"      Dobutamine echo mortality-I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/40/20110\" title=\"figure 5\">",
"      SPECT imaging and outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/24/24962\" title=\"figure 6\">",
"      Dipyridamole stress and outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1497|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/8/6284\" title=\"table 1\">",
"      Pretest probability of CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/46/17132\" title=\"table 2\">",
"      Pretest probability of CHD in CASS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/11/15548\" title=\"table 3A\">",
"      ACC AHA ETT risk assess CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/46/33516\" title=\"table 3B\">",
"      ACC AHA choice imaging risk I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/30/27116\" title=\"table 4\">",
"      Noninvasive risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/51/31548\" title=\"table 5\">",
"      ACC AHA angiography for stable angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=related_link\">",
"      Electrocardiographic changes during exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=related_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35945?source=related_link\">",
"      Performance of exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25754?source=related_link\">",
"      Risk factors for adverse outcomes after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20138?source=related_link\">",
"      Role of stress testing after coronary revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_58_2987="PNS manifestations Lyme";
var content_f2_58_2987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Peripheral nervous system manifestations of neuroborreliosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manifestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Mononeuropathy multiplex",
"       </td>",
"       <td>",
"        Cranial neuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiculoneuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mononeuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mononeuropathy multiplex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plexopathy (brachial, lumbosacral)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confluent mononeuropathy multiplex, simulating diffuse polyneuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demyelinating",
"       </td>",
"       <td>",
"        Rarely reported, questionable causality",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2987=[""].join("\n");
var outline_f2_58_2987=null;
var title_f2_58_2988="Drugs cause hyperprolactinemia";
var content_f2_58_2988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Partial list of drugs known to cause hyperprolactinemia and/or galactorrhea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Typical antipsychotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenothiazine drugs (eg, chlorpromazine [Thorazine], clomipramine [Anafranil], fluphenazine [Prolixin], prochlorperazine [Compazine], thioridazine [Mellaril])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Haloperidol (Haldol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pimozide (Orap)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Atypical antipsychotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risperidone (Risperdal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Molindone (Moban)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Olanzapine (Zyprexa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antidepressant agents*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clomipramine (Anafranil)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Desipramine (Norpramin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cimetidine (Tagamet)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metoclopramide (Reglan)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antihypertensive agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methyldopa (Aldomet)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reserpine (Hydromox, Serpasil, others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Verapamil (Calan, Isoptin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Opiates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Codeine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Morphine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * One study also found an association between hyperprolactinemia in adolescent girls and the use of selective serotoninc reuptake inhibitors, including fluoxetine (Prozac), fluvoxamine (Luvox), and divalproex (Depakote).",
"    </div>",
"    <div class=\"reference\">",
"     Jerrell JM, Bacon J, Burgis JT, Menon S. Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents. J Adolesc Health 2009; 45:79.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2988=[""].join("\n");
var outline_f2_58_2988=null;
var title_f2_58_2989="Glasgow and pediatric coma scales";
var content_f2_58_2989=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glasgow coma scale and pediatric Glasgow coma scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Sign",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glasgow Coma Scale",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pediatric Glasgow Coma Scale",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Eye opening",
"       </td>",
"       <td>",
"        Spontaneous",
"       </td>",
"       <td>",
"        Spontaneous",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To command",
"       </td>",
"       <td>",
"        To sound",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        To pain",
"       </td>",
"       <td>",
"        To pain",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        Verbal response",
"       </td>",
"       <td>",
"        Oriented",
"       </td>",
"       <td>",
"        Age-appropriate vocalization, smile, or orientation to sound, interacts (coos, babbles), follows objects",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Confused, disoriented",
"       </td>",
"       <td>",
"        Cries, irritable",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inappropriate words",
"       </td>",
"       <td>",
"        Cries to pain",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incomprehensible sounds",
"       </td>",
"       <td>",
"        Moans to pain",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        Motor response",
"       </td>",
"       <td>",
"        Obeys commands",
"       </td>",
"       <td>",
"        Spontaneous movements (obeys verbal command)",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Localizes pain",
"       </td>",
"       <td>",
"        Withdraws to touch (localizes pain)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Withdraws",
"       </td>",
"       <td>",
"        Withdraws to pain",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal flexion to pain",
"       </td>",
"       <td>",
"        Abnormal flexion to pain (decorticate posture)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abnormal extension to pain",
"       </td>",
"       <td>",
"        Abnormal extension to pain (decerebrate posture)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"3\">",
"        <strong>",
"         Best total score",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The Glasgow coma scale (GCS) is scored between 3 and 15, 3 being the worst, and 15 the best. It is composed of three parameters: best eye response (E), best verbal response (V), and best motor response (M). The components of the GCS should be recorded individually; for example, E2V3M4 results in a GCS of 9. A score of 13 or higher correlates with mild brain injury; a score of 9 to 12 correlates with moderate injury; and a score of 8 or less represents severe brain injury. The pediatric Glasgow coma scale (PGCS) was validated in children 2 years of age or younger.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Teasdale G and Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81.",
"       </li>",
"       <li>",
"        Holmes JF, Palchak MJ, MacFarlane T, Kuppermann N. Performance of the pediatric Glasgow coma scale in children with blunt head trauma. Acad Emerg Med 2005; 12:814.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2989=[""].join("\n");
var outline_f2_58_2989=null;
var title_f2_58_2990="Indications pacing modes I";
var content_f2_58_2990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76319%7ECARD%2F55317%7ECARD%2F69138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76319%7ECARD%2F55317%7ECARD%2F69138&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for different pacing modes - I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mode",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generally agreed upon indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Controversial indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VVI",
"       </td>",
"       <td>",
"        Atrial fibrillation with symptomatic bradycardia in the chronotropically competent patient",
"       </td>",
"       <td>",
"        Symptomatic bradycardia in the patient with associated terminal illness or other medical conditions from which recovery is not anticipated and pacing is life-sustaining only",
"       </td>",
"       <td>",
"        <p>",
"         Patients with known pacemaker syndrome or hemodynamic deterioration with ventricular pacing at the time of implant",
"        </p>",
"        <p>",
"         Chronotropic incompetent patient who will benefit from rate response",
"        </p>",
"        <p>",
"         Patients with hemodynamic need for dual-chamber pacing",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VVIR",
"       </td>",
"       <td>",
"        Fixed atrial arrhythmias (atrial fibrillation or flutter) with symptomatic bradycardia in the chronotropically incompetent patient",
"       </td>",
"       <td>",
"        As for VVI",
"       </td>",
"       <td>",
"        As for VVI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AAI",
"       </td>",
"       <td>",
"        Symptomatic bradycardia as a result of sinus node dysfunction in the otherwise chronotropically competent patient and when AV conduction can be proven normal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Sinus node dysfunction with associated AV block either demonstrated spontaneously or during pre-implant testing",
"        </p>",
"        <p>",
"         When adequate atrial sensing cannot be attained",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AAIR",
"       </td>",
"       <td>",
"        Symptomatic bradycardia as a result of sinus node dysfunction in the otherwise chronotropically incompetent patient and when AV conduction can be proven normal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        As for AAI",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for different pacing modes - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mode",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generally agreed upon indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Controversial indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DVI*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VDD&bull;",
"       </td>",
"       <td>",
"        <p>",
"         Congenital AV block",
"        </p>",
"        <p>",
"         AV block when sinus node function can be proven normal",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Sinus node dysfunction",
"        </p>",
"        <p>",
"         AV block when accompanied by sinus",
"        </p>",
"        <p>",
"         node dysfunction",
"        </p>",
"        <p>",
"         When adequate atrial sensing cannot be attained",
"        </p>",
"        <p>",
"         AV block when accompanied by paroxysmal supraventricular tachycardias",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VDDR&Delta;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * DVI as a stand-alone pacing mode, ie a pacemaker capable of DVI as the only dual-chamber mode of operation, is obselete. All primary uses of this mode should be considered individually.",
"     <br>",
"      &bull; VDD as a stand-alone pacing mode, ie a pacemaker capable of VDD as the only dual-chamber mode of operation, is currently used primarily as a single-lead VDD system. If a dual lead system is implanted, then the capability of DDD pacing is desirable.",
"      <br>",
"       &Delta; In current single-lead VDDR pacemakers, p-wave tracking occurs as long as the sinus rate is appropriate. However, in the presence of sinus bradycardia or chronotropic incompetence, the pacemaker operates in the VVIR mode.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for different pacing modes - III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mode",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generally agreed upon indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Controversial indications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDI",
"       </td>",
"       <td>",
"        Need for dual-chamber pacing in the presence of significant PSVT in the CC patient",
"       </td>",
"       <td>",
"        Sinus node dysfunction in the absence of AV block in the presence of of significant PSVT in the CC patient",
"       </td>",
"       <td>",
"        Chronotropic incompetence in the patient with a demonstrated need or improvement with rate responsiveness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDIR*",
"       </td>",
"       <td>",
"        AV block and sinus node dysfunction in the CI patient in the presence of significant PSVT",
"       </td>",
"       <td>",
"        Sinus node dysfunction without AV block in the CI patient in the presence of significant PSVT",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDD",
"       </td>",
"       <td>",
"        <p>",
"         AV block and sinus node dysfunction in the CC patient",
"        </p>",
"        <p>",
"         Need for AV synchrony to maximize cardiac output in CC active patients",
"        </p>",
"        <p>",
"         Previous pacemaker syndrome",
"        </p>",
"       </td>",
"       <td>",
"        For any rhythm disturbance when atrial sensing and capture is possible for the potential purpose of minimizing future atrial fibrillation and improved morbidity and survival",
"       </td>",
"       <td>",
"        <p>",
"         Presence of chronic atrial fibrillation, atrial flutter, giant inexcitable atrium or other frequent paroxysmal supraventricular tachyarrhythmias",
"        </p>",
"        <p>",
"         When adequate atrial sensing cannot be attained",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DDDR",
"       </td>",
"       <td>",
"        AV block and sinus node dysfunction in the CI patient",
"       </td>",
"       <td>",
"        As for DDD",
"       </td>",
"       <td>",
"        As for DDD",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CC: chronotropically competent, ie, the ability to achieve an appropriate heart rate for a given physiologic activity; CI: chronotropically incompetent, ie, the inability to achieve an appropriate heart rate for a given physiologic activity; PSVT: paroxysmal supraventricular tachycardia.",
"     <br>",
"      * DDIR is being supplanted by DDD or DDDR pacemakers with the capability of mode-switching, ie, the pacemaker automatically reprograms to a mode incapable of tracking the atrial rhythm in the presence of an atrial rhythm that the pacemaker classifies as a pathological rhythm. When the pacemaker recognizes the atrial rhythm as being physiological, the pacemaker reprograms to the previously programmed mode.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2990=[""].join("\n");
var outline_f2_58_2990=null;
var title_f2_58_2991="Montelukast and exercise";
var content_f2_58_2991=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The FEV1 after exercise in patients who received montelukast (A) and salmeterol (B)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 437px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The mean response curves are shown for percentage change in FEV",
"    <sub>",
"     1",
"    </sub>",
"    from prechallenge FEV",
"    <sub>",
"     1",
"    </sub>",
"    at baseline (closed circles), days 1 to 3 (closed squares), week 4 (open squares), and week 8 (open circles) after study treatment.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in&nbsp;one second.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Edelman, et al. Ann Intern Med, 2000; 132:100.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_58_2991=[""].join("\n");
var outline_f2_58_2991=null;
